var title_f26_41_27280="Pathophysiology of achalasia";
var content_f26_41_27280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of achalasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the pathophysiology of achalasia which results from the degeneration of neurons in the esophageal wall. Histologic examination reveals decreased numbers of neurons (ganglion cells) in the myenteric plexuses, and the ganglion cells that remain often are surrounded by lymphocytes and, less prominently, by eosinophils. This inflammatory degeneration preferentially involves the nitric oxide-producing, inhibitory neurons that effect the relaxation of esophageal smooth muscle, resulting in an elevation in basal lower esophageal sphincter&nbsp;(LES) pressure and an inability of the sphincter muscle to relax normally; the cholinergic neurons that contribute to LES tone by causing smooth muscle contraction are relatively spared",
"    <sup>",
"     [1]",
"    </sup>",
"    . In some patients, degenerative changes also are found in the ganglion cells of the dorsal motor nucleus of the vagus in the brainstem, and Wallerian degeneration has been observed in the vagal fibers that supply the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      &nbsp; 1. Holloway RH, Dodds WJ, Helm JF, et al. Integrity of cholinergic innervation to the lower esophageal sphincter in achalasia. Gastroenterology 1986; 90:924.",
"      <br>",
"       Reprinted, courtesy of the Clinical Teaching Project of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner- Fenwick, Inc. at 1-800-432-8433.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27280=[""].join("\n");
var outline_f26_41_27280=null;
var title_f26_41_27281="X linked inheritance";
var content_f26_41_27281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    X linked inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27281=[""].join("\n");
var outline_f26_41_27281=null;
var title_f26_41_27282="Diagnosis of CAPS with APS or aPL";
var content_f26_41_27282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75604%7ERHEUM%2F66464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75604%7ERHEUM%2F66464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis of catastrophic antiphospholipid syndrome (APS): Patients with APS or persistent positive antiphospholipid antibody",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Catastrophic antiphospholipid syndrome (APS) diagnosis in patients with history of APS or persistent antiphospholipid antibody (aPL)-positivity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10:74. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 651px\">",
"   <div class=\"ttl\">",
"    Diagnosis of catastrophic antiphospholipid syndrome (APS): Patients lacking history of APS or persistent positive antiphospholipid antibody",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 631px; height: 613px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Catastrophic antiphospholipid syndrome (APS) diagnosis in patients without history of APS or persistent antiphospholipid antibody (aPL)positivity.",
"    <div class=\"footnotes\">",
"     * Our recommendation for the definition of \"positive aPL\" is: lupus anticoagulant (LA) test positive based on the guidelines of International Society of Haemostasis; anticardiolipin antibody (aCL) IgG/M &ge;40 U, and/or anti&beta;2glycoproteinl antibody (a&beta;2GPI) IgG/M &ge;40 U. Caution and further assessment(s) are required if: a) LA test is performed in anticoagulated patients; b) aCL or a&beta;2GPI IgG/M titers are in the range of 20-39 U; and/or c) aCL or a&beta;2GPI IgA is the only positive aPL ELISA test.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      \"Positive aPL\" twice 12 weeks apart (of note, the original Sapporo APS classification criteria required two positive aPL tests 6 weeks apart, which has been changed to 12 weeks as part of the updated Sapporo APS classification criteria).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10:74. Illustration used with the permission from Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27282=[""].join("\n");
var outline_f26_41_27282=null;
var title_f26_41_27283="Major histocompatibility complex (MHC) structure and function";
var content_f26_41_27283=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major histocompatibility complex (MHC) structure and function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27283/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27283/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27283/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27283/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27283/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27283/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/41/27283/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal antigenic barrier to transplantation is a series of molecules which are polypeptide products of a closely linked cluster of genes known, in humans, as the major histocompatibility complex (MHC) or human leukocyte antigens (HLA) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/1\">",
"     1",
"    </a>",
"    ]. The MHC is highly polymorphic from individual to individual and segregates in families in a Mendelian codominant fashion.",
"   </p>",
"   <p>",
"    The following is a general overview of MHC structure and function. Details of MHC use in transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=see_link\">",
"     \"HLA matching and graft survival in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MHC CLASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genes of the HLA locus are located on the short arm of chromosome six. They encode two distinct classes of cell surface molecules: class I and class II [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/2\">",
"     2",
"    </a>",
"    ]. Class I molecules are expressed on the surfaces of virtually all nucleated cells at varying densities, while class II molecules are more restricted to cells of the immune system, primarily B lymphocytes and monocytes. However, cytokines secreted by lymphocytes and monocytes during immune activation can cause dramatic increases in class II HLA antigen expression, even on cell types that normally have little or no surface expression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three different class I (HLA-A, -B, -C) and class II (HLA-DQ, -DR, -DP) antigens. Studies in renal transplantation indicate that mismatches at the A, B, and DR loci are associated with worse allograft survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=see_link\">",
"     \"HLA matching and graft survival in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal function of the MHC is now better understood. The principal task of the immune system is to distinguish self from non-self. HLA molecules provide the crucial surface upon which the antigen receptors on T lymphocytes recognize foreign (non-self) antigens. On antigen presenting cells such as macrophages, class II molecules present antigenic fragments to the CD4+ inducer (or helper) T cells, while class I molecules function at the effector phase of immunity by presenting antigens to CD8+ T cells, which generally have cytotoxic or suppressor function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/1\">",
"     1",
"    </a>",
"    ]. This process of antigen presentation consists of the binding of a single T cell receptor to a complex on the surface of an antigen presenting cell consisting of the MHC molecule and a peptide fragment derived from the foreign antigen (",
"    <a class=\"graphic graphic_figure graphicRef53512 \" href=\"UTD.htm?37/38/38499\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63541 \" href=\"UTD.htm?6/23/6527\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Via the use of molecular biologic techniques, such as screenings of cDNA, cosmid, and yeast artificial chromosome libraries and genomic sequencing, an ever expanding number of immune-related genes has been found in additional areas of the MHC, the class III and class IV regions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/4\">",
"     4",
"    </a>",
"    ]. These contiguous regions lie between the class I and class II genomic areas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The class III region contains several components of the complement system, C4, C2 and Bf. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"       \"Overview and clinical assessment of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The class IV region, located between the class III and I areas, is comprised of a relatively large cluster of immune-related genes. These include tumor necrosis factor-alpha and -beta, as well as numerous less characterized genes or gene families, such as B144, AIF-1, and the MIC family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MHC STRUCTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crystallization of the class I HLA-A2 molecule has permitted visualization of how antigen presentation might occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/5\">",
"     5",
"    </a>",
"    ]. X-ray diffraction analysis reveals a distinct groove on the external face of the molecule that is 20 x 10 x 10 &Aring; in size. This site can bind antigen peptide fragments containing eight to nine amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], although it appears that recognition involves the binding of only two amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/8\">",
"     8",
"    </a>",
"    ]; how this might occur is not known. The sides of the groove are formed by two alpha-helical structures, and the floor is formed by eight antiparallel beta pleats. Other class I alleles and at least the class II HLA-DR1 molecule have a virtually identical core structure; however, the bound peptide in the class II molecules is longer, containing 13 to 26 amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Membrane bound class I consists of an alpha chain (mol wt 44 kD) with three domains: a3 is close to the cell membrane, while a1 and a2 contain polymorphic sites and form the peptide binding groove, each contributing one alpha helix and half of the beta pleated floor. The class I complex also consists of non-covalently associated &szlig;2-microglobulin (mol wt 12 kD), which stabilizes the complex by fitting under the a3 domain.",
"   </p>",
"   <p>",
"    Class II molecules have a somewhat different structure. They contain two transmembrane chains (alpha and beta for each locus); each chain is approximately 24 kD in size and has two domains. The two distal domains associate non-covalently to form the peptide binding pocket described above [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/9\">",
"     9",
"    </a>",
"    ]. There is no association of class II molecules with &szlig;2-microglobulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF ANTIGEN PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign antigens initially do not exist in small fragments. Thus, antigen presenting cells (such as macrophages) must have the intracellular machinery to perform the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Make peptides for MHC association from larger proteins",
"     </li>",
"     <li>",
"      Bring the self MHC-peptide complex to the cell surface",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The processing pathways are somewhat different for class I and class II molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27283/abstract/10\">",
"     10",
"    </a>",
"    ]. A detailed discussion of the mechanism of antigen presentation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11727703\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genes of the human leukocyte antigen (HLA) locus, which are located on the short arm of chromosome six, encode two distinct classes of cell surface molecules that function to distinguish self from non-self; class I major histocompatibility (MHC) molecules are expressed on the surfaces of virtually all nucleated cells at varying densities, while class II MHC molecules are generally restricted to cells of the immune system, primarily B lymphocytes and monocytes. There are three different class I (HLA-A, -B, -C) and class II (HLA-DQ, -DR, -DP) antigens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'MHC classes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The class III region of the MHC encodes genes for complement proteins, and the class IV region encodes other immune response-related genes, including those for tumor necrosis factor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'MHC classes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A distinct groove on the external face of the class I and II molecules can bind antigen peptide fragments. Membrane bound class I consists of an alpha chain (mol wt 44 kD) with three domains that is non-covalently associated &szlig;2- microglobulin (mol wt 12 kD), which stabilizes the complex. Class II molecules contain two transmembrane chains (alpha and beta for each locus); each chain is approximately 24 kD in size and has two domains. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'MHC structure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antigen presenting cells (such as macrophages) have the intracellular machinery to make peptides for MHC association from larger proteins and to bring the self MHC-peptide complex to the cell surface. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of antigen presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/1\">",
"      Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/2\">",
"      Duquesnoy RJ, Trucco M. Genetic basis of cell surface polymorphisms encoded by the major histocompatibility complex in humans. Crit Rev Immunol 1988; 8:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/3\">",
"      Halloran PF, Wadgymar A, Autenried P. The regulation of expression of major histocompatibility complex products. Transplantation 1986; 41:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/4\">",
"      Gruen JR, Weissman SM. Evolving views of the major histocompatibility complex. Blood 1997; 90:4252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/5\">",
"      Bjorkman PJ, Saper MA, Samraoui B, et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/6\">",
"      Falk K, R&ouml;tzschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 1990; 348:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/7\">",
"      R&ouml;tzschke O, Falk K. Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol Today 1991; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/8\">",
"      Bjorkman PJ. MHC restriction in three dimensions: a view of T cell receptor/ligand interactions. Cell 1997; 89:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/9\">",
"      Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27283/abstract/10\">",
"      Krensky AM. The HLA system, antigen processing and presentation. Kidney Int Suppl 1997; 58:S2.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3969 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27283=[""].join("\n");
var outline_f26_41_27283=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11727703\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MHC CLASSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MHC STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF ANTIGEN PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11727703\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/3969\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/3969|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/38/38499\" title=\"figure 1\">",
"      HLA TCR complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6527\" title=\"figure 2\">",
"      Antigen presentation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_41_27284="Dermatomyositis - hyperpigmentation";
var content_f26_41_27284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented patches are present on the upper back of this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27284=[""].join("\n");
var outline_f26_41_27284=null;
var title_f26_41_27285="Diagnosis of meningococcal infection";
var content_f26_41_27285=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of meningococcal infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27285/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27285/contributors\">",
"     Michael Apicella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27285/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27285/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27285/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27285/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27285/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/41/27285/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neisseria meningitidis is the second most common cause of community-acquired adult bacterial meningitis in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/1\">",
"     1",
"    </a>",
"    ]. Since routine vaccination of infants with the Haemophilus influenzae type b capsular conjugate vaccine was introduced, N. meningitidis has become the leading cause of bacterial meningitis in children and adolescents in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Causative organisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of meningococcal disease can be quite varied, ranging from transient fever and bacteremia to fulminant disease with death ensuing within hours of the onset of clinical symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of meningococcal infection will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The gold standard for the diagnosis of systemic meningococcal infection is the isolation of N. meningitidis from a usually sterile body fluid such as blood or cerebrospinal fluid (CSF), or less commonly synovial, pleural, or pericardial fluid.",
"   </p>",
"   <p>",
"    The microbiology, pathogenesis, epidemiology, treatment and prevention of N. meningitidis infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=see_link\">",
"     \"Microbiology and pathobiology of Neisseria meningitidis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link\">",
"     \"Treatment and prevention of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGIC DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to isolate the organism not only to confirm an etiology of infection but also to perform antibiotic susceptibility testing. Meningococci with increasing resistance to the penicillins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , and cephalosporins have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/1,5-9\">",
"     1,5-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Blood culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of positive blood cultures is 50 to 60 percent, a much lower rate than the frequency of positive CSF cultures (80 to 90 percent), even in patients without overt meningeal signs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation of the CSF in a patient with suspected bacterial meningitis is a Gram stain by a qualified individual. Gram stain is as valuable as latex agglutination, even in partially treated meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/16\">",
"     16",
"    </a>",
"    ]. Bacterial counts in the CSF from patients with meningococcal meningitis have ranged from 1.5 x 10",
"    <sup>",
"     2",
"    </sup>",
"    to 6 x 10",
"    <sup>",
"     7",
"    </sup>",
"    organisms (mean 1.3 x 10",
"    <sup>",
"     5",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy may play a role in the diagnosis of meningococcal infection. This issue was addressed in a prospective study of the use of Gram stain and culture from biopsies of skin lesions in 31 patients with suspected meningococcal infection and 12 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/18\">",
"     18",
"    </a>",
"    ]. The sensitivity of cultures of blood, CSF, and skin biopsies was 56, 50, and 36 percent, respectively. When culture and Gram stain were combined, the sensitivity was 56, 64, and 56 percent, respectively. In three patients, the diagnosis of meningococcal infection was based solely upon positive skin biopsy results.",
"   </p>",
"   <p>",
"    Thus, Gram stain and culture of a skin lesion can increase the diagnostic yield. However, negative results do",
"    <strong>",
"     not",
"    </strong>",
"    exclude the diagnosis of meningococcal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pretreatment with antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy should",
"    <strong>",
"     not",
"    </strong>",
"    be delayed waiting for completion of the lumbar puncture. Blood cultures should be drawn and plans to institute antibiotic and supportive therapy should begin as soon as the diagnosis of bacterial meningitis is seriously considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'Laboratory features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pretreatment with antibiotics can substantially diminish the probability of a positive CSF culture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] and the time interval between antibiotic administration and negative CSF cultures in children with meningococcal meningitis may be shorter than appreciated. This was illustrated in a study in which lumbar puncture (LP) was performed after antibiotics were given or serial LPs were performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/21\">",
"     21",
"    </a>",
"    ]. Among children with meningococcal meningitis who were treated with a parenteral dose of an extended-spectrum cephalosporin, three of nine LPs were sterile within one hour (one as early as 15 minutes) and all were sterile by two hours. Sterilization of the CSF was substantially slower with pneumococcal (four to ten hours) and group B streptococcal infection (more than eight hours).",
"   </p>",
"   <p>",
"    In contrast to the rapid clearance of meningococcus from the CSF, a small study that assessed the utility of Gram stain and culture from skin biopsies found no correlation between the yield of skin biopsies and previous antibiotic treatment, suggesting slower clearance than from the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CEREBROSPINAL FLUID PROFILE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemistry and cytologic findings suggestive of bacterial meningitis include a CSF glucose concentration below 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    a protein concentration above 500",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and a white cell count above",
"    <span class=\"nowrap\">",
"     1000/microL.",
"    </span>",
"    However, one or more of the classic findings is often absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'CSF analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LATEX AGGLUTINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercial kits utilizing latex beads coated with antibodies to meningococcal capsular antigens are available for use in body fluids other than blood (eg, CSF and urine) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These kits can detect agglutination of five capsular types: A, B, C, Y, and W135. The sensitivity for serogroup B is low, and false negative results can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/25\">",
"     25",
"    </a>",
"    ]. This potential deficiency of the test is especially important because serogroup B has been common in infections in the United States and Western Europe and this serogroup is not a component of the current meningococcal vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POLYMERASE CHAIN REACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymerase chain reaction (PCR), which detects small quantities of bacterial DNA, has the potential to be an important tool in the rapid diagnosis of meningococcal infection. PCR has a number of advantages compared to culture for the diagnosis of meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/22,26-33\">",
"     22,26-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can establish the diagnosis more rapidly, when available as an in-hospital test. PCR results are often available on the day of presentation compared to one or two days or more for culture confirmation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since viable bacteria are not required, sensitivity is not affected by prior antibiotic administration, which can sterilize the cerebrospinal fluid within one to two hours [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It can rapidly type strains, a useful adjunct in situations that appear to be an epidemic in evolution [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiplex PCR permits simultaneous testing for meningococcal, pneumococcal, and Haemophilus influenzae infection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The performance of real-time PCR was assessed in a report of 24 patients with meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/22\">",
"     22",
"    </a>",
"    ]. The sensitivity and specificity were 96 and 100 percent; in contrast, the sensitivity of CSF or blood culture was only 63 percent. In all nine patients in whom blood was tested more than once, PCR remained positive longer than culture after the initiation of antibiotic therapy; in three patients, more than 72 hours longer.",
"   </p>",
"   <p>",
"    Bacterial load of N. meningitidis DNA level by real-time PCR has been associated with mortality, development of permanent sequelae (eg, limb loss, skin grafting), and prolonged hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/35\">",
"     35",
"    </a>",
"    ]. Infections caused by serogroup C were associated with a higher bacterial load and an increased risk of death.",
"   </p>",
"   <p>",
"    Despite these benefits, PCR has not replaced traditional culture methods because it cannot be used to determine antimicrobial susceptibility and is not routinely performed by most hospital laboratories. Another limitation is that false negative results can occur with N. meningitidis isolates that possess gene polymorphisms, particularly when a single gene is targeted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27285/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gold standard for the diagnosis of systemic meningococcal infection is the isolation of N. meningitidis by culture from a usually sterile body fluid such as blood or cerebrospinal fluid (CSF) or, less commonly, synovial, pleural, or pericardial fluid. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolation of the organism by culture confirms an etiology of infection and permits antibiotic susceptibility testing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Blood culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gram stain and culture of a skin lesion can increase the diagnostic yield, although a negative result does not exclude the diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Skin biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic therapy should",
"      <strong>",
"       not",
"      </strong>",
"      be delayed waiting for performance of lumbar puncture. Blood cultures should be drawn and plans to institute antibiotic and supportive therapy should begin as soon as the diagnosis of bacterial meningitis is seriously considered. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pretreatment with antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemistry and cytologic findings suggestive of bacterial meningitis include a CSF glucose concentration below 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      a protein concentration above 500",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and a white cell count above",
"      <span class=\"nowrap\">",
"       1000/microL.",
"      </span>",
"      However, one or more of the classic findings is often absent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cerebrospinal fluid profile'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Commercial latex agglutination kits, which utilize latex beads coated with antibodies to meningococcal capsular antigens, are available for use in body fluids such as CSF and urine. These kits can detect agglutination of five capsular types: A, B, C, Y, and W135, but the sensitivity for serogroup B is low. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Latex agglutination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The polymerase chain reaction (PCR) is a sensitive and rapid tool for diagnosing meningococcal infection. However, PCR has not replaced traditional culture methods because it cannot be used to determine antimicrobial susceptibility and is not routinely performed by most hospital laboratories. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Polymerase chain reaction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/1\">",
"      Angyo IA, Okpeh ES. Changing patterns of antibiotic sensitivity and resistance during an outbreak of meningococcal infection in Jos, Nigeria. J Trop Pediatr 1998; 44:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/2\">",
"      Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/3\">",
"      Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med 2006; 355:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/4\">",
"      Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/5\">",
"      Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med 1998; 339:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/6\">",
"      Sprott MS, Kearns AM, Field JM. Penicillin-insensitive Neisseria meningitidis. Lancet 1988; 1:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/7\">",
"      Mendelman PM, Campos J, Chaffin DO, et al. Relative penicillin G resistance in Neisseria meningitidis and reduced affinity of penicillin-binding protein 3. Antimicrob Agents Chemother 1988; 32:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/8\">",
"      S&aacute;ez-Nieto JA, Lujan R, Berr&oacute;n S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1992; 14:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/9\">",
"      Fangio P, Desbouchages L, Lach&eacute;rade JC, et al. Neisseria meningitidis C:2b:P1.2,5 with decreased susceptibility to penicillin isolated from a patient with meningitis and purpura fulminans. Eur J Clin Microbiol Infect Dis 2005; 24:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/10\">",
"      HOYNE AL, BROWN RH. Seven hundred and twenty seven meningococcic cases; an analysis. Ann Intern Med 1948; 28:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/11\">",
"      TOBIN JL. Complications of meningococcus infection in a series of sixty-three consecutive sporadic cases. Am J Med Sci 1956; 231:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/12\">",
"      McCracken GH Jr. Rapid identification of specific etiology in meningitis. J Pediatr 1976; 88:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/13\">",
"      CARPENTER RR, PETERSDORF RG. The clinical spectrum of bacterial meningitis. Am J Med 1962; 33:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/14\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/15\">",
"      Levin S, Painter MB. The treatment of acute meningococcal infection in adults. A reappraisal. Ann Intern Med 1966; 64:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/16\">",
"      Finlay FO, Witherow H, Rudd PT. Latex agglutination testing in bacterial meningitis. Arch Dis Child 1995; 73:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/17\">",
"      Feldman WE. Relation of concentrations of bacteria and bacterial antigen in cerebrospinal fluid to prognosis in patients with bacterial meningitis. N Engl J Med 1977; 296:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/18\">",
"      Arend SM, Lavrijsen AP, Kuijken I, et al. Prospective controlled study of the diagnostic value of skin biopsy in patients with presumed meningococcal disease. Eur J Clin Microbiol Infect Dis 2006; 25:643.",
"     </a>",
"    </li>",
"    <li>",
"     Tunkel AR, Scheld WM. Acute meningitis. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.1083.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/20\">",
"      Bohr V, Rasmussen N, Hansen B, et al. 875 cases of bacterial meningitis: diagnostic procedures and the impact of preadmission antibiotic therapy. Part III of a three-part series. J Infect 1983; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/21\">",
"      Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics 2001; 108:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/22\">",
"      Bryant PA, Li HY, Zaia A, et al. Prospective study of a real-time PCR that is highly sensitive, specific, and clinically useful for diagnosis of meningococcal disease in children. J Clin Microbiol 2004; 42:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/23\">",
"      Muller PD, Donald PR, Burger PJ, van der Horst W. Detection of bacterial antigens in cerebrospinal fluid by a latex agglutination test in 'septic unknown' meningitis and serogroup B meningococcal meningitis. S Afr Med J 1989; 76:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/24\">",
"      Borel T, Rose AM, Guillerm M, et al. High sensitivity and specificity of the Pastorex latex agglutination test for Neisseria meningitidis serogroup A during a clinical trial in Niger. Trans R Soc Trop Med Hyg 2006; 100:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/25\">",
"      McGraw TP, Bruckner DA. Evaluation of the Directigen and Phadebact agglutination tests. Am J Clin Pathol 1984; 82:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/26\">",
"      Ni H, Knight AI, Cartwright K, et al. Polymerase chain reaction for diagnosis of meningococcal meningitis. Lancet 1992; 340:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/27\">",
"      Newcombe J, Cartwright K, Palmer WH, McFadden J. PCR of peripheral blood for diagnosis of meningococcal disease. J Clin Microbiol 1996; 34:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/28\">",
"      Borrow R, Claus H, Chaudhry U, et al. siaD PCR ELISA for confirmation and identification of serogroup Y and W135 meningococcal infections. FEMS Microbiol Lett 1998; 159:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/29\">",
"      Speers DJ, Jelfs J. Typing of Neisseria meningitidis by restriction analysis of the amplified porA gene. Pathology 1997; 29:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/30\">",
"      Newcombe J, Dyer S, Blackman L, et al. PCR-single-stranded confirmational polymorphism analysis for non-culture-based subtyping of meningococcal strains in clinical specimens. J Clin Microbiol 1997; 35:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/31\">",
"      Diggle MA, Clarke SC. Detection and genotyping of meningococci using a nested PCR approach. J Med Microbiol 2003; 52:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/32\">",
"      Diggle MA, Clarke SC. Molecular methods for the detection and characterization of Neisseria meningitidis. Expert Rev Mol Diagn 2006; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/33\">",
"      Meningococcal Reference Unit, Gray SJ, Trotter CL, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/34\">",
"      Corless CE, Guiver M, Borrow R, et al. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J Clin Microbiol 2001; 39:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/35\">",
"      Darton T, Guiver M, Naylor S, et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis 2009; 48:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/36\">",
"      Cavrini F, Liguori G, Andreoli A, Sambri V. Multiple nucleotide substitutions in the Neisseria meningitidis serogroup C ctrA gene cause false-negative detection by real-time PCR. J Clin Microbiol 2010; 48:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27285/abstract/37\">",
"      Jaton K, Ninet B, Bille J, Greub G. False-negative PCR result due to gene polymorphism: the example of Neisseria meningitidis. J Clin Microbiol 2010; 48:4590.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1281 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27285=[""].join("\n");
var outline_f26_41_27285=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGIC DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Blood culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pretreatment with antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CEREBROSPINAL FLUID PROFILE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LATEX AGGLUTINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POLYMERASE CHAIN REACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=related_link\">",
"      Microbiology and pathobiology of Neisseria meningitidis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_41_27286="Nadroparin: Drug information";
var content_f26_41_27286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nadroparin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/45/5845?source=see_link\">",
"    see \"Nadroparin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fraxiparine&trade;;",
"     </li>",
"     <li>",
"      Fraxiparine&trade; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Low Molecular Weight Heparin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose expressed as anti-Xa international units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of clotting during hemodialysis:",
"     </b>",
"     Single dose of 65 units/kg into arterial line at start of each dialysis session; may give additional dose if session lasts longer than 4 hours; adjust dose during subsequent dialysis sessions to plasma anti-Xa levels of 0.5-1 anti-Xa units/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients at risk of hemorrhage:",
"     </i>",
"     Administer 32.5 units/kg; may give additional smaller dose if session lasts longer than 4 hours; adjust dose during subsequent dialysis sessions to plasma anti-Xa levels of 0.2-0.4 anti-Xa units/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thromboprophylaxis therapy:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      General surgery:",
"     </i>",
"     Initial: 2850 units administered 2-4 hours preoperatively; Maintenance: SubQ: 2850 units once daily. Continue therapy for at least 7 days and until ambulant or no longer at DVT risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hip replacement surgery:",
"     </i>",
"     38 units/kg (maximum dose: 3800 units) administered 12 hours preoperatively and repeated at 12 hours postoperatively then followed by 38 units/kg once daily (maximum dose: 3800 units) up to and including postoperative day 3; postoperative day 4 begin 57 units/kg once daily (maximum dose: 5700 units) . Continue therapy for at least 10 days and until ambulant or no longer at DVT risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of DVT:",
"     </b>",
"     SubQ: 171 units/kg once daily (maximum dose: 17,100 units/day); expected plasma anti-Xa levels are 1.2-1.8 anti-Xa units/mL 3-4 hours postinjection.",
"     <b>",
"      Note:",
"     </b>",
"     Patients at an increased risk of bleeding should receive a dose of 86 units/kg every 12 hours with expected plasma anti-Xa levels of 0.5-1.1 anti-Xa units/mL 3-4 hours postinjection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of unstable angina and non-Q-wave myocardial infarction (in conjunction with aspirin):",
"     </b>",
"     Initial: I.V.: 86 units/kg bolus. Maintenance: SubQ: 86 units/kg every 12 hours (usual treatment duration: 6 days); plasma anti-Xa levels should be &lt;1.2 anti-Xa units/mL 3-4 hours postinjection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion to oral anticoagulation therapy:",
"     </b>",
"     Continue nadroparin until therapeutic INR has been achieved with vitamin K antagonist (usually at least 5 days).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F199029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: Dosage adjustment not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30-50 mL/minute: Reduce dose by 25% to 33%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prophylaxis: Reduce dose by 25% to 33%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13219378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fraxiparine&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9500 anti-Xa units/mL (0.2 mL, 0.3 mL, 0.4 mL) [ungraduated prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9500 anti-Xa units/mL (0.6 mL, 0.8 mL, 1 mL) [graduated prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fraxiparine&trade; Forte: 19,000 anti-Xa units/mL (0.6 mL, 0.8 mL, 1 mL) [graduated prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F199008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by SubQ injection into anterolateral abdominal wall with subsequent doses to be administered alternately on right and left side of abdominal wall. The thigh may also be used. Do",
"     <b>",
"      not",
"     </b>",
"     administer intramuscularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     May be administered I.V. only as initial bolus dose for unstable angina and non-Q-wave myocardial infarction.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of thromboembolic disorders (particularly deep venous thrombosis and pulmonary embolism) in general and orthopedic surgery; treatment of deep venous thrombosis; prevention of clotting during hemodialysis; treatment of unstable angina and non-Q-wave myocardial infarction",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     As with all anticoagulants, bleeding is the major adverse effect of nadroparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arterial/venous thrombosis, thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema (very rare), cutaneous necrosis (rare), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoaldosteronism (causing hyperkalemia and/or hyponatremia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Priapism (very rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematological: Bleeding, eosinophilia (very rare), thrombocytopenia, thrombocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Calcinosis, injection site hematoma, pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Osteopenic effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactoid reactions (very rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Erythema, pruritus, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nadroparin, any component of the formulation, or to other low molecular weight heparins and/or heparin; acute infective endocarditis; active bleeding or increased risk of hemorrhage (hemostasis disorder); history of confirmed or suspected immunologically mediated heparin-induced thrombocytopenia (HIT) (delayed-onset severe thrombocytopenia) or positive",
"     <i>",
"      in vitro",
"     </i>",
"     test for antiplatelet antibodies in the presence of nadroparin; major blood clotting disorders; hemorrhagic tendency or other conditions involving increase risk of bleeding; organic lesions likely to bleed (active peptic ulceration); hemorrhagic cerebrovascular event (unless systemic emboli present); severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; injuries to or operations on the CNS, eyes, or ears; severe renal insufficiency (creatinine clearance &lt;30 mL/minute when used for treatment); concomitant use of spinal/epidural anesthesia with repeated high-dose nadroparin",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of nadroparin in patients with current HIT or HIT with thrombosis is",
"     <b>",
"      not",
"     </b>",
"     recommended and considered contraindicated due to high cross-reactivity to heparin-platelet factor-4 antibody (Guyatt [ACCP], 2012; Warkentin, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding (eg, severe hepatic disease, patients undergoing knee surgery, concomitant therapy with platelet inhibitors, elderly). Discontinue if bleeding occurs. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmology surgery; in patients  treated concomitantly with platelet inhibitors; recent GI bleeding; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Discontinue if bleeding occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cutaneous necrosis: Cutaneous necrosis preceded by purpura or infiltrated or painful erythematous blotches has been reported rarely; discontinue treatment immediately if suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia possibly by suppressing aldosterone production. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, renal dysfunction, concomitant use of potassium-sparing diuretics or potassium supplements, hematoma in body tissues).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Cases of thrombocytopenia including thrombocytopenia with thrombosis have occurred. Use with caution in patients with history of thrombocytopenia (drug-induced or congenital) or platelet defects; monitor platelet count closely. Use is contraindicated in patients with a history of confirmed or suspected heparin-induced thrombocytopenia or positive",
"     <i>",
"      in vitro",
"     </i>",
"     test for antiplatelet antibodies in the presence of nadroparin. Discontinue therapy and consider alternative treatment if platelets are &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or thrombosis develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with history of peptic ulcer disease; contraindicated in patients with active ulceration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prosthetic heart valves: Prosthetic valve thrombosis has been reported in patients receiving thromboprophylaxis therapy with LMWHs. Pregnant women may be at increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; primarily renally excreted. Dose reductions may be required. Use is contraindicated in severe renal impairment when treating thromboembolic disorders, unstable angina, and NSTEMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging (needle cover of prefilled syringe) may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     administer intramuscularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other LMWHs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Knee surgery: Risk of bleeding may be increased in patients undergoing knee surgery and receiving LMWHs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuraxial anesthesia: Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal) or spinal puncture in patients anticoagulated with LMWH or heparinoids. Consider risk versus benefit prior to spinal procedures; risk is increased by concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as traumatic or repeated epidural or spinal punctures. Avoid lumbar puncture or spinal or epidural anesthesia for 12 hours following the last nadroparin prophylactic dose or 24 hours following the last nadroparin treatment dose. Nadroparin therapy should not be resumed for at least 2 hours after anesthesia procedures. Longer intervals should be considered for patients with renal impairment. Observe patient closely for bleeding and signs and symptoms of neurological impairment if therapy is administered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Heparin (Low Molecular Weight) may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Potential benefits of therapeutic doses of LMW heparins should be weighed against an increased risk of bleeding in patients who receive drotrecogin alfa.  In patients receiving prophylactic LMW heparin doses consider continuing this during drotrecogin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palifermin: Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Heparin (Low Molecular Weight).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F199022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, garlic, ginseng (all have anticoagulant or antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F199014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported. LMWH is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors.  LMWH should be discontinued prior to induction of labor or a planned cesarean delivery. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14081018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of LMWH have been detected in breast milk; however, because it has a low oral bioavailability, it is unlikely to cause adverse events in a nursing infant. Use of LMWH may be continued in breast-feeding women (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F199003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet counts (at baseline and then twice weekly during therapy), bleeding complications including stool occult blood tests, hemoglobin, antifactor Xa levels (recommended to obtain levels 4 hours postdose in patients at increased risk for bleeding [eg, elderly, body weight &lt;45 kg or &gt;120 kg, renal impairment, pregnant women, and children]); renal function, hepatic function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F14081019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-Xa level target (measured 4 hours after administration): Treatment of venous thromboembolism (Garcia, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"     1.3 Anti-Xa units/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Twice-daily dosing:",
"     </i>",
"     0.6-1 Anti-Xa units/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fraxiparin (AT, DE, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Fraxiparina (BR, ES, IT, PT, VE);",
"     </li>",
"     <li>",
"      Fraxiparine (AR, AU, BE, BG, CH, CL, CN, CZ, EC, EE, FI, FR, GR, HK, HR, HU, ID, IL, IN, KP, LU, MX, MY, NL, NO, NZ, PH, PK, PL, PY, RU, SE, SG, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Fraxiparine Forte (PH, SG, TH);",
"     </li>",
"     <li>",
"      Fraxiparine TX (CO, CR, MX, PE, UY);",
"     </li>",
"     <li>",
"      Fraxodi (BE, GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nadroparin has high anti-Xa activity, but low anti-IIa activity. The greater ratio of anti-Xa activity has the potential to provide equivalent antithrombic efficacy with reduced hemorrhagic complications.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Anti-Xa activity: 18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~3.6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: &ge;89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.5 hours (prolonged in renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Davis R and Faulds D, &ldquo;Nadroparin Calcium. A Review of Its Pharmacology and Clinical Use in the Prevention and Treatment of Thromboembolic Disorders,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1997, 10(4):299-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27286/abstract-text/9108990/pubmed\" id=\"9108990\" target=\"_blank\">",
"        9108990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):24-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27286/abstract-text/22315264/pubmed\" id=\"22315264\" target=\"_blank\">",
"        22315264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27286/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagge J, Crowther M, and Hirsh J, &ldquo;Is Impaired Renal Function a Contraindication to the Use of Low-Molecular Weight Heparin?&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2002, 162:2605-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27286/abstract-text/12456233/pubmed\" id=\"12456233\" target=\"_blank\">",
"        12456233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nutescu EA, Spinler SA, Wittkowsky A, et al, &ldquo;Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2009, 43(6):1064-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27286/abstract-text/19458109/pubmed\" id=\"19458109\" target=\"_blank\">",
"        19458109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turpie AG, &ldquo;Can We Differentiate the Low-Molecular-Weight Heparins?&rdquo;",
"      <i>",
"       Clin Cardiol",
"      </i>",
"      , 2000, 23(Suppl I):4-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27286/abstract-text/10680023/pubmed\" id=\"10680023\" target=\"_blank\">",
"        10680023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE and Barkin RL, &ldquo;Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(2):181-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27286/abstract-text/10030768/pubmed\" id=\"10030768\" target=\"_blank\">",
"        10030768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10060 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27286=[""].join("\n");
var outline_f26_41_27286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199025\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199059\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199028\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062283\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199029\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13219378\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076317\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234097\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199008\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199007\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199064\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199057\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199011\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198994\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299734\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198998\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199022\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199014\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199031\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081018\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199003\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081019\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199015\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198993\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199010\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10060|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/45/5845?source=related_link\">",
"      Nadroparin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_41_27287="Timolol (systemic): Drug information";
var content_f26_41_27287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Timolol (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/60/22469?source=see_link\">",
"    see \"Timolol (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/9/16534?source=see_link\">",
"    see \"Timolol (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9600170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Timol&reg;;",
"     </li>",
"     <li>",
"      Nu-Timolol;",
"     </li>",
"     <li>",
"      Teva-Timolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9600485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9600252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 10 mg twice daily, increase gradually every 7 days, usual dosage: 20-40 mg/day in 2 divided doses; maximum: 60 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of myocardial infarction:",
"     </b>",
"     Oral: 10 mg twice daily initiated within 1-4 weeks after infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"     Oral: Initial: 10 mg twice daily, increase to maximum of 30 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9600253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9600179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of hypertension and angina; to reduce mortality following myocardial infarction; prophylaxis of migraine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9600173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Timolol may be confused with atenolol, Tylenol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9600200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Frequency not defined:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, arrhythmia, cardiac arrest, cardiac failure, cerebral ischemia, cerebral vascular accident, edema, heart block, hypotension, palpitation, Raynaud's phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, depression, disorientation, hallucinations, insomnia, memory loss, nervousness, nightmares, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, pseudopemphigoid, psoriasiform rash, psoriasis exacerbation, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia masked, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence, retoperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Claudication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myasthenia gravis exacerbation, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Corneal sensitivity decreased, cystoid macular edema, diplopia, dry eyes, keratitis, ocular discharge, ocular pain, ptosis, refractive changes, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, nasal congestion, pulmonary edema, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, cold hands/feet, Peyronie's disease, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9600185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to timolol or any component of the formulation; sinus bradycardia; sinus node dysfunction; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure; bronchospastic disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9600197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; can worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment;  marked hypotension can occur in patients maintained on hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal:",
"     <b>",
"      [U.S. Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia.",
"     </b>",
"     Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9600203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies timolol as pregnancy category C. Timolol crosses the placenta and decreased fetal heart rate has been observed following maternal use of oral and ophthalmic timolol during pregnancy. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother; however, timolol is currently not recommended for the initial treatment of hypertension in pregnancy. If timolol is required for the treatment of glaucoma during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease exposure to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9600183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/ consider risk:benefit (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9600184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol is excreted into breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Due to the potential for adverse events, nursing infants (especially those with cardiorespiratory problems) should be monitored.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9600254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered with food at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9600287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Timolol Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $63.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $78.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $145.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9600257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, apical and radial pulses, fluid I &amp; O, daily weight, respirations, mental status, and circulation in extremities before and during therapy; monitor for systemic effect of beta-blockade",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betim (GB);",
"     </li>",
"     <li>",
"      Blocadren (AT, IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9600221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors; reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow, produces a negative chronotropic and inotropic activity through an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9600223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hypotensive: 15-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 0.5-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete (~90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2D6; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-2.7 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (15% to 20% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, \"ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mundorf TK, Ogawa T, Naka H, et al, &ldquo;A 12-Month, Multicenter, Randomized, Double-Masked, Parallel-Group Comparison of Timolol-LA Once Daily and Timolol Maleate Ophthalmic Solution Twice Daily in the Treatment of Adults With Glaucoma or Ocular Hypertension,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2004, 26(4):541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/15189751/pubmed\" id=\"15189751\" target=\"_blank\">",
"        15189751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, \"Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinetics",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Hear J",
"      </i>",
"      , 2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/41/27287/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9945 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-94DF4A431B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27287=[""].join("\n");
var outline_f26_41_27287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600170\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600176\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600485\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600252\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600253\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600285\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600178\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600179\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600173\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600200\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600185\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600197\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600203\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600204\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600180\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600181\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600183\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600184\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600254\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600287\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600257\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390238\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600221\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600223\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9945\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9945|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=related_link\">",
"      Timolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=related_link\">",
"      Timolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=related_link\">",
"      Timolol (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/60/22469?source=related_link\">",
"      Timolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/9/16534?source=related_link\">",
"      Timolol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_41_27288="Simple and mixed acid-base disorders";
var content_f26_41_27288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Simple and mixed acid-base disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27288/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27288/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27288/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/41/27288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12584019\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each day approximately 15,000 mmol (considerably more with exercise) of carbon dioxide (CO2, which can generate carbonic acid as it combines with water) and 50 to 100 meq of nonvolatile acid (mostly sulfuric acid derived from the metabolism of sulfur-containing amino acids) are produced. Acid-base balance is maintained by normal pulmonary and renal excretion of carbon dioxide and nonvolatile acid, respectively.",
"   </p>",
"   <p>",
"    Renal excretion of acid is achieved by combining hydrogen ions with either urinary buffers to form titratable acid, mainly phosphate (HPO42- &nbsp;+ &nbsp;H+ &rarr; H2PO4-), or with ammonia to form ammonium (NH3 &nbsp;+ &nbsp;H+ &rarr; NH4+) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link\">",
"     \"Chapter 11A: Renal hydrogen excretion\"",
"    </a>",
"    .) When increased quantities of acid must be excreted by the kidney, the major adaptive response consists of increases in ammonia production (derived from the metabolism of glutamine) with a resultant increase in ammonium excretion into the urine.",
"   </p>",
"   <p>",
"    Acid-base status is usually assessed by measuring the components of the bicarbonate-carbon dioxide buffer system in blood:",
"   </p>",
"   <p>",
"    &nbsp;Dissolved CO2 &nbsp;+ &nbsp;H2O &nbsp;&harr; &nbsp;H2CO3 &nbsp;&harr; &nbsp;HCO3- &nbsp;+ &nbsp;H+",
"   </p>",
"   <p>",
"    When blood gas analysis is carried out, the partial pressure of CO2 (PCO2) and the pH are each measured using specific electrodes. The serum bicarbonate (HCO3-) concentration is then calculated with the Henderson-Hasselbalch equation. Generally, the PCO2 is reported in mmHg, and HCO3- in",
"    <span class=\"nowrap\">",
"     meq/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;pH &nbsp; = &nbsp; 6.10 &nbsp; + &nbsp; log &nbsp;([HCO3-] &nbsp;&divide; &nbsp;[0.03 &nbsp;x &nbsp;PCO2])",
"   </p>",
"   <p>",
"    where the pH is equal to (-log [H+]), 6.10 is the negative log of Ka (-log Ka) which is the dissociation constant for this reaction, 0.03 is the solubility coefficient for CO2 in blood, and the PCO2 is the partial pressure of carbon dioxide in blood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23224?source=see_link\">",
"     \"Chapter 10B: Buffers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the HCO3 is measured in venous blood, it is usually measured directly as \"total CO2\" with an ion-selective electrode. The directly measured venous HCO3- is generally about 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    greater than the simultaneously calculated arterial HCO3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102629685\">",
"    <span class=\"h1\">",
"     NORMAL VALUES ACCORDING TO SITE OF SAMPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of normal values for acid-base parameters is different for arterial and venous samples and also varies among laboratories. These issues are discussed in detail elsewhere but will be briefly summarized here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=see_link\">",
"     \"Venous blood gases and other alternatives to arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360547531\">",
"    <span class=\"h2\">",
"     Arterial sample",
"    </span>",
"    &nbsp;&mdash;&nbsp;For an arterial sample, the normal range for pH is 7.36 to 7.44; for bicarbonate (HCO3) concentration, 21 to 27",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    and for PCO2, 36 to 44 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360547538\">",
"    <span class=\"h2\">",
"     Peripheral venous sample",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal values for peripheral venous blood differ from those of arterial blood due to the uptake and buffering of metabolically produced CO2 in the capillary circulation. If a tourniquet is used to facilitate phlebotomy, it should be released about one minute before the sample is drawn to avoid changes induced by ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In different studies, the peripheral venous range for pH is approximately 0.02 to 0.04 pH units lower than in arterial blood, the HCO3 concentration is approximately 1 to 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    higher, and the PCO2 is approximately 3 to 8 mmHg higher [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. If venous measurements are used for serial monitoring, periodic correlation with arterial measurements should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37165540\">",
"    <span class=\"h2\">",
"     Central venous sample",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous samples may be used in patients with central venous catheters. The central venous pH is usually 0.03 to 0.05 pH units lower than in arterial blood and the PCO2 is 4 to 5 mmHg higher, with little or no increase in serum HCO3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584039\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF ACID-BASE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following definitions of acid-base disorders are based upon principles of the Henderson-Hasselbalch equation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acidemia &mdash; An arterial pH below the normal range (less than 7.36).",
"     </li>",
"     <li>",
"      Alkalemia &mdash; An arterial pH above the normal range (greater than 7.44).",
"     </li>",
"     <li>",
"      Acidosis &mdash; A process that tends to lower the extracellular fluid pH (hydrogen ion concentration increases). This can be caused by a fall in the serum bicarbonate (HCO3) concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevation in PCO2.",
"     </li>",
"     <li>",
"      Alkalosis &mdash; A process that tends to raise the extracellular fluid pH (hydrogen ion concentration decreases). This can be caused by an elevation in the serum HCO3 concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a fall in PCO2.",
"     </li>",
"     <li>",
"      Metabolic acidosis &mdash; A disorder that causes reductions in the serum HCO3 concentration and pH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"       \"Approach to the adult with metabolic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic alkalosis &mdash; A disorder that causes elevations in the serum HCO3 concentration and pH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link\">",
"       \"Pathogenesis of metabolic alkalosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"       \"Causes of metabolic alkalosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory acidosis &mdash; A disorder that causes an elevation in arterial PCO2 and a reduction in pH.",
"     </li>",
"     <li>",
"      Respiratory alkalosis &mdash; A disorder that causes a reduction in arterial PCO2 and an increase in pH.",
"     </li>",
"     <li>",
"      Simple acid-base disorder &mdash; The presence of one of the above four disorders with the appropriate respiratory or renal compensation for that disorder. (See",
"      <a class=\"local\" href=\"#H12584047\">",
"       'Compensatory respiratory and renal responses'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      Mixed acid-base disorder &mdash; The simultaneous presence of more than one acid-base disorder. Mixed acid-base disorders can be suspected from the patient's history, from a lesser- or greater-than-expected compensatory respiratory or renal response, and from analysis of the serum electrolytes and anion gap. As an example, a patient with severe vomiting would be expected to develop a metabolic alkalosis due to the loss of acidic gastric fluid. If, however, the patient developed hypovolemic shock from the fluid loss, the ensuing lactic acidosis would lower the elevated serum HCO3 possibly to below normal values, resulting in acidemia. (See",
"      <a class=\"local\" href=\"#H94198601\">",
"       'Mixed acid-base disorders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584047\">",
"    <span class=\"h1\">",
"     COMPENSATORY RESPIRATORY AND RENAL RESPONSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141686354\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Henderson-Hasselbalch equation described above shows that the pH is determined by the ratio of the serum bicarbonate (HCO3) concentration and the PCO2, not by the value of either one alone. Each of the simple acid-base disorders is associated with a compensatory respiratory or renal response that limits the change in ratio and therefore in pH (",
"    <a class=\"graphic graphic_figure graphicRef79833 \" href=\"UTD.htm?41/44/42691\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a metabolic acid-base disorder causes the serum HCO3 to decrease (metabolic acidosis) or increase (metabolic alkalosis), there is usually an appropriate respiratory compensation that causes the PCO2 to change in the",
"      <strong>",
"       same direction",
"      </strong>",
"      as the serum HCO3 (falling in metabolic acidosis and rising in metabolic alkalosis). The respiratory compensation mitigates the change in the ratio of the serum HCO3 to PCO2 and therefore in the pH. The respiratory compensation in metabolic acidosis or alkalosis is a rapid response that, in metabolic acidosis, begins within 30 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/10\">",
"       10",
"      </a>",
"      ] and is complete within 12 to 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When a respiratory acid-base disorder causes the PCO2 to increase (respiratory acidosis) or decrease (respiratory alkalosis), there is usually a renal compensation that causes the HCO3 to change in the",
"      <strong>",
"       same direction",
"      </strong>",
"      as the PCO2, thereby mitigating the change in pH. These compensations are mediated by increased hydrogen ion secretion (which raises the serum HCO3 concentration) in respiratory acidosis and decreased hydrogen ion secretion and urinary HCO3 loss in respiratory alkalosis. The renal compensation takes three to five days for completion. As a result, the expected findings are different in acute (little or no renal compensation) and chronic (full renal compensation) respiratory acid-base disorders. (See",
"      <a class=\"local\" href=\"#H12584082\">",
"       'Respiratory acid-base disorders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The compensatory renal and respiratory responses are thought to be mediated, at least in part, by parallel pH changes within sensory and regulatory cells including renal tubule cells and cells in the respiratory center [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/12\">",
"     12",
"    </a>",
"    ]. The magnitude of the compensatory response is proportional to the severity of the primary acid-base disturbance.",
"   </p>",
"   <p>",
"    An important clinical consequence of these compensations is that the diagnosis of an acid-base disorder requires measurement of the extracellular (usually arterial) pH. The diagnosis",
"    <strong>",
"     cannot",
"    </strong>",
"    be made from the serum HCO3 alone. A low value could represent either metabolic acidosis or the renal compensation to respiratory alkalosis, while a high value could represent either metabolic alkalosis or the renal compensation to respiratory acidosis. In addition, mixed acid-base disorders may be present. (See",
"    <a class=\"local\" href=\"#H94198601\">",
"     'Mixed acid-base disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The expected compensation for any given acid-base disorder has been determined empirically by observations in humans with either spontaneous or experimentally induced simple acid-base disorders (",
"    <a class=\"graphic graphic_figure graphicRef79833 \" href=\"UTD.htm?41/44/42691\">",
"     figure 1",
"    </a>",
"    ). The degree of compensation is usually calculated from the decrease or increase in arterial PCO2 from its normal range (in metabolic acid-base disorders) or the decrease or increase in serum HCO3 from its normal range (in respiratory acid-base disorders). This approach presumes that the patient had normal values prior to the onset of the acid-base disorder. Thus, in the absence of known baseline values, there is the potential for error if the patient had abnormal baseline values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351038132\">",
"    <span class=\"h2\">",
"     Metabolic acid-base disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584056\">",
"    <span class=\"h3\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory compensation to metabolic acidosis results in an approximately 1.2 mmHg fall in arterial PCO2 for every 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    reduction in the serum HCO3 concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. The respiratory response to metabolic acidosis begins within 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/10\">",
"     10",
"    </a>",
"    ] and is complete within 12 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/11\">",
"     11",
"    </a>",
"    ]. The lag in respiratory compensation is not seen when the metabolic acidosis develops slowly (eg, 4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    fall in serum HCO3 over 15 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/11\">",
"     11",
"    </a>",
"    ]. An inability to generate the expected respiratory response is usually indicative of significant underlying respiratory or neurologic disease, but can also be seen in patients with acute metabolic acidosis in whom there has not been adequate time for respiratory compensation to achieve completion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other relationships have been used to determine the appropriate respiratory compensation to metabolic acidosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial PCO2 &nbsp;= &nbsp;1.5 &nbsp;x &nbsp;serum HCO3 &nbsp;+ &nbsp;8 &plusmn; 2 (Winters' equation) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arterial PCO2 &nbsp;= &nbsp;Serum HCO3 &nbsp;+ &nbsp;15",
"     </li>",
"     <li>",
"      Arterial PCO2 should be similar to the decimal digits of the arterial pH (eg, 25 mmHg when the arterial pH is 7.25, a setting in which the serum HCO3 concentration would be approximately 11",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These formulas generally give similar results and there are no data on comparative efficacy. (See",
"    <a class=\"local\" href=\"#H351037906\">",
"     'Case 2'",
"    </a>",
"    below.) A reasonable approach is to use the relationship rule that is easiest to remember and implement.",
"   </p>",
"   <p>",
"    There is a limit to the maximum respiratory compensation that can be attained. In severe metabolic acidosis (eg, serum HCO3 concentration less than 6",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    the PCO2 can be reduced to a minimum of 8 to 12 mmHg in individuals with normal neuro-respiratory function.",
"   </p>",
"   <p>",
"    In addition to assessing the respiratory compensation, another component in the evaluation of patients with metabolic acidosis is calculation of the serum anion gap to determine if it is normal or elevated. Metabolic acidosis may be of the high anion gap type, normal anion gap type (hyperchloremic) or combined normal and elevated anion gap acidosis. The latter often occurs with severe diarrhea, which generates a normal anion gap metabolic acidosis but can also lead to hypovolemia-induced lactic acidosis. With high anion gap metabolic acidosis, comparing the change in anion gap (or the",
"    <span class=\"nowrap\">",
"     &Delta;anion",
"    </span>",
"    gap) with the change in bicarbonate (or the",
"    <span class=\"nowrap\">",
"     &Delta;bicarbonate)",
"    </span>",
"    may be helpful. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584074\">",
"    <span class=\"h3\">",
"     Metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory compensation to metabolic alkalosis should raise the PCO2 by 0.7 mmHg for every 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    elevation in the serum HCO3 concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,17,18\">",
"     9,17,18",
"    </a>",
"    ]. In severe metabolic alkalosis, the arterial PCO2 can be as high as 55 mmHg, suggesting that hypoxia in individuals without underlying lung disease does not usually limit the respiratory compensation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351038251\">",
"    <span class=\"h3\">",
"     Limitations of the respiratory compensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been shown in dog studies that respiratory compensation for metabolic acidosis or alkalosis most effectively blunts changes in pH acutely. If the metabolic disorder persists, on the other hand, respiratory compensation becomes less effective and can even have a detrimental effect on pH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,19,20\">",
"     9,19,20",
"    </a>",
"    ]. The acute hyperventilatory response to metabolic acidosis causes a fall in PCO2 and this will initially raise the arterial pH toward normal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,19,20\">",
"     9,19,20",
"    </a>",
"    ]. However, over time, the reduction in PCO2 causes a further decrease in the serum HCO3 concentration due to both reduced renal acid secretion and urinary HCO3 loss; these changes are similar to those induced by primary respiratory alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12584098\">",
"     'Respiratory alkalosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The net effect of these two processes is that they tend to cancel one another out so that the arterial pH with chronic metabolic acidosis is often the same whether or not respiratory compensation occurs. Furthermore, in studies in dogs, the respiratory response was occasionally maladaptive, and the secondary fall in serum HCO3 actually caused the arterial pH to fall below the level that would have existed in the absence of respiratory compensation. &nbsp;",
"   </p>",
"   <p>",
"    Analogous findings have been demonstrated in chronic metabolic alkalosis in which the respiratory compensation (hypoventilation leading to a rise in PCO2) causes increased renal acid secretion and a rise in the serum HCO3 concentration similar to that induced by primary respiratory acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/20\">",
"     20",
"    </a>",
"    ]. The renal response to a high PCO2 mitigates the pH benefit of hypoventilation. As with chronic metabolic acidosis, studies in dogs showed that this effect could become maladaptive and raise the arterial pH to a value higher than that which would have occurred in the absence of respiratory compensation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584082\">",
"    <span class=\"h2\">",
"     Respiratory acid-base disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The compensatory response to respiratory acid-base disorders occurs in two stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial acute response is generated by blood, extracellular fluid, and cell buffering that causes the serum HCO3 to increase (in respiratory acidosis) or decrease (in respiratory alkalosis) within minutes. The acute response is relatively modest.",
"     </li>",
"     <li>",
"      A larger response generated by the kidney is called chronic compensation. This response begins soon after the onset of the primary respiratory disorder but requires",
"      <strong>",
"       3 to 5 days",
"      </strong>",
"      to become complete. Because of this variation with time, different compensatory responses are expected with acute and chronic respiratory disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With chronic respiratory acidosis, the kidney increases acid excretion in the form of titratable acid and ammonium, and also increases HCO3 reabsorption to maintain the higher HCO3 concentration (",
"      <a class=\"graphic graphic_figure graphicRef63315 \" href=\"UTD.htm?30/38/31341\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With chronic respiratory alkalosis, the kidney reduces acid excretion, and also excretes some HCO3 to reduce the HCO3 concentration. Renal tubular reabsorption of HCO3 is also reduced.",
"     </li>",
"     <li>",
"      These renal responses are carefully regulated. As an example, administering exogenous HCO3 in the setting of chronic respiratory acidosis and relatively normal renal function results in the urinary excretion of the excess alkali without a further elevation in the serum HCO3 concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584090\">",
"    <span class=\"h3\">",
"     Respiratory acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The compensatory response to acute respiratory acidosis causes the serum HCO3 concentration to increase by about 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 10 mmHg elevation in the PCO2 (",
"    <a class=\"graphic graphic_figure graphicRef58687 \" href=\"UTD.htm?14/22/14702\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,24\">",
"     9,24",
"    </a>",
"    ]. If the elevated PCO2 persists, the serum HCO3 will continue to gradually increase and, after three to five days, the disorder is considered chronic. Studies mostly performed in hospitalized patients found that the serum HCO3 increases by 3.5 to 4.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 10 mmHg elevation in PCO2 in patients with chronic respiratory acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,21,22,25\">",
"     9,21,22,25",
"    </a>",
"    ]. However, a later study in stable outpatients with chronic respiratory acidosis found a greater compensatory rise in serum HCO3 of about 5.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per 10 mmHg elevation in PCO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The compensatory response to mild to moderate chronic respiratory acidosis (PCO2 less than 70 mmHg) results in an arterial pH that is usually modestly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,21,22,25\">",
"     9,21,22,25",
"    </a>",
"    ] or in the low-normal range (",
"    <a class=\"graphic graphic_figure graphicRef63315 \" href=\"UTD.htm?30/38/31341\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, moderate to severe acidemia in a patient with mild to moderate chronic respiratory acidosis is usually indicative of concurrent metabolic acidosis or superimposed acute respiratory acidosis. An arterial pH of 7.40 or higher suggests a concurrent metabolic alkalosis or acute respiratory alkalosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584098\">",
"    <span class=\"h3\">",
"     Respiratory alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The compensatory response to acute respiratory alkalosis causes the serum HCO3 concentration to fall by 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 10 mmHg decline in the PCO2 (",
"    <a class=\"graphic graphic_figure graphicRef58687 \" href=\"UTD.htm?14/22/14702\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,24\">",
"     9,24",
"    </a>",
"    ]. If the reduced PCO2 persists for more than 3 to 5 days, then the disorder is considered chronic and the serum HCO3 concentration should fall by about 4 to 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 10 mmHg reduction in the PCO2 (",
"    <a class=\"graphic graphic_figure graphicRef75327 \" href=\"UTD.htm?20/14/20717\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27288/abstract/9,27\">",
"     9,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584115\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four primary acid-base disorders: metabolic acidosis, metabolic alkalosis, respiratory acidosis, and respiratory alkalosis. Because the renal compensation to respiratory disorders takes 3 to 5 days to complete, the primary respiratory disorders can be further divided into acute and chronic respiratory acidosis and respiratory alkalosis. An important clinical consequence of the respiratory and renal compensations to acid-base disorders is that the diagnosis",
"    <strong>",
"     cannot",
"    </strong>",
"    be made with certainty from the serum HCO3 alone. As an example, a low value could represent either metabolic acidosis or the renal compensation to respiratory alkalosis, while a high value could represent either metabolic alkalosis or the renal compensation to respiratory acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360547043\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate diagnosis of an acid-base disorder requires measurement of serum electrolytes to determine the serum HCO3 concentration, the serum potassium (looking for hypokalemia or hyperkalemia which can accompany many metabolic acid-base disorders), and the serum sodium and chloride concentrations to detect possible hyponatremia or hypernatremia and calculation of the serum anion gap. In addition, in patients with a high anion gap metabolic acidosis, analysis of the increase of the anion gap from its baseline divided by the reduction in bicarbonate from normal (ie, the",
"    <span class=\"nowrap\">",
"     &Delta;anion",
"    </span>",
"    gap divided by the",
"    <span class=\"nowrap\">",
"     &Delta;bicarbonate,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     \"&Delta;/&Delta;\")",
"    </span>",
"    may be helpful. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A definitive diagnosis of acid-base disorders requires measurement of the arterial pH and PCO2 to identify the underlying disorder and to determine whether a mixed acid-base disorder exists. However, measurement of arterial pH may not be required when the history and serum electrolytes clearly point toward a particular diagnosis. As an example, arterial blood gas analysis might not be required in a previously healthy patient with a recent history of severe diarrhea who has a low serum bicarbonate, hypokalemia, a normal anion gap, and no apparent cause of chronic respiratory alkalosis in which a low serum bicarbonate would represent the compensatory response.",
"   </p>",
"   <p>",
"    Measurement of peripheral venous pH and PCO2 is an alternative, less invasive and more convenient approach than arterial measurements. However, venous measurements have some important limitations. As a result, arterial measurements are preferred. If venous measurements are used for serial monitoring, periodic correlation with arterial measurements should be performed. These issues are discussed in detail elsewhere. (See",
"    <a class=\"local\" href=\"#H102629685\">",
"     'Normal values according to site of sampling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest the following three-step approach in most patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1: Establish the primary diagnosis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Metabolic acidosis is characterized by a low serum HCO3 and a low arterial pH; the serum anion gap may be increased or normal",
"     </li>",
"     <li>",
"      Metabolic alkalosis is characterized by an elevated serum HCO3 and an elevated arterial pH",
"     </li>",
"     <li>",
"      Respiratory acidosis is characterized by an elevated arterial PCO2 and a low arterial pH",
"     </li>",
"     <li>",
"      Respiratory alkalosis is characterized by low arterial PCO2 and an elevated arterial pH",
"     </li>",
"     <li>",
"      Compensatory responses do not usually return the arterial pH to normal. Thus, a normal arterial pH in the presence of substantial changes in both serum HCO3 and arterial PCO2 is usually indicative of a",
"      <strong>",
"       mixed",
"      </strong>",
"      acid-base disorder (which could include an acute respiratory alkalosis produced by hyperventilation due to the discomfort of obtaining the blood sample). However, there are two exceptions in which a simple acid-base disorder may be accompanied by a normal arterial pH. Specifically, compensatory responses may return the arterial pH to the high-normal range with mild to moderate chronic respiratory alkalosis (",
"      <a class=\"graphic graphic_figure graphicRef75327 \" href=\"UTD.htm?20/14/20717\">",
"       figure 4",
"      </a>",
"      ), and to the low-normal range with mild to moderate chronic respiratory acidosis (",
"      <a class=\"graphic graphic_figure graphicRef63315 \" href=\"UTD.htm?30/38/31341\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H94198601\">",
"       'Mixed acid-base disorders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 2: Assess the degree of compensation as defined above for the individual disorders. A substantially reduced or excessive compensation is indicative of a",
"      <strong>",
"       mixed",
"      </strong>",
"      acid-base disorder. (See",
"      <a class=\"local\" href=\"#H12584047\">",
"       'Compensatory respiratory and renal responses'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The degree of compensation is usually calculated from the change in arterial PCO2 (in metabolic acid-base disorders) or serum HCO3 (in respiratory acid-base disorders) from their presumed baseline normal values. The assumption that the patient had normal values prior to the onset of the acid-base disorder may be incorrect and introduces potential error.",
"      <br/>",
"      <br/>",
"      The compensatory response must be correlated with the history. This is particularly true in respiratory acid-base disorders since the renal compensation occurs over 3 to 5 days. Thus, the expected compensation is smaller with acute compared with chronic disorders. As noted above, the normal compensatory response to respiratory acidosis is an increase in the serum HCO3 concentration by about 1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for every 10 mmHg elevation in the PCO2 acutely and about 3.5 to 5.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for every 10 mmHg elevation in the PCO2 if the underlying respiratory problem persists for three to five days or more. (See",
"      <a class=\"local\" href=\"#H12584090\">",
"       'Respiratory acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Step 3: In patients with metabolic acidosis, determine if the anion gap is elevated. If it is, then analyze the ratio of the increase in anion gap to the decrease in the HCO3 concentration. This is the",
"      <span class=\"nowrap\">",
"       &Delta;anion",
"      </span>",
"      <span class=\"nowrap\">",
"       gap/&Delta;HCO3",
"      </span>",
"      ratio. Interpretation of the anion gap and the",
"      <span class=\"nowrap\">",
"       &Delta;anion",
"      </span>",
"      <span class=\"nowrap\">",
"       gap/&Delta;HCO3",
"      </span>",
"      ratio are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"       \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Step 4: Establish the clinical diagnosis. Once the acid-base disorder is identified, the underlying cause or causes of the disorder should be determined and corrected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377752461\">",
"    <span class=\"h3\">",
"     Case 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with respiratory distress and an uncertain past history presents with an arterial pH of 7.32, an arterial PCO2 of 70 mmHg, and a serum HCO3 concentration of 35",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which is approximately 11",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    above the value seen in normal individuals. These values are compatible with the expected renal compensation to chronic respiratory acidosis, although they are also compatible with a mixed acid-base disorder. As an example, an acute respiratory acidosis causing a rise in PCO2 to 70 mmHg should increase the serum HCO3 by 3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to about 27",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    If, however, this respiratory disturbance is superimposed on a metabolic alkalosis that raises the serum HCO3 by an additional 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to 35",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the resulting findings would be the same as those seen with a simple chronic respiratory acidosis. The history usually helps to distinguish among these possibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351037906\">",
"    <span class=\"h3\">",
"     Case 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with diarrhea has an arterial pH of 7.24, HCO3 concentration of 10",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and arterial PCO2 of 24 mmHg. The low pH indicates acidemia, and the low serum HCO3 concentration indicates metabolic acidosis. The serum HCO3 concentration of 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    is approximately 14",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    below normal. This should generate a 17 mmHg fall in the PCO2 (14 &nbsp;x &nbsp;1.2 &nbsp;= &nbsp;17) from 40 to 23 mmHg. Thus, this patient has a simple metabolic acidosis. The other estimation equations for the degree of compensation cited above give similar results. Winters' equation predicts a PCO2 of 23 mmHg (1.5 x 10 +8 &plusmn; 2), the \"HCO3 + 15\" rule predicts a PCO2 of 25 mmHg, and the pCO2 is the same as the decimal digits of the arterial pH. (See",
"    <a class=\"local\" href=\"#H12584056\">",
"     'Metabolic acidosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A PCO2 significantly higher than the expected value would indicate a concurrent respiratory acidosis, as might occur if the patient were obtunded and had respiratory center depression. If, on the other hand, the PCO2 were lower than 20 mmHg, then a concurrent respiratory alkalosis would be present. The combination of metabolic acidosis and respiratory alkalosis is often seen with salicylate intoxication or septic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link&amp;anchor=H8#H8\">",
"     \"Salicylate (aspirin) poisoning in adults\", section on 'Acid-base abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94198601\">",
"    <span class=\"h2\">",
"     Mixed acid-base disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have two, three, or more relatively independent acid-base disorders. These mixed disorders include combinations of metabolic disorders (eg, vomiting-induced metabolic alkalosis plus hypovolemia-induced lactic acidosis), mixed metabolic and respiratory disorders (eg, metabolic acidosis and respiratory alkalosis in salicylate intoxication), and more complex combinations.",
"   </p>",
"   <p>",
"    As discussed in the preceding section, the evaluation of patients with acid-base disorders initially requires identification of the major disorder, and then determination if the degree of compensation is appropriate. If the compensation is",
"    <strong>",
"     not",
"    </strong>",
"    appropriate, then this is indicative of a second acid-base disorder (ie, a mixed acid-base disorder is present). The following examples are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If metabolic acidosis is the primary disorder, an arterial PCO2 substantially higher than the expected compensatory response defines the mixed disorder of metabolic acidosis and respiratory acidosis, while an arterial PCO2 substantially lower than expected defines the mixed disorder of metabolic acidosis and respiratory alkalosis (which could be produced by acute hyperventilation due to the discomfort of obtaining the blood sample).",
"     </li>",
"     <li>",
"      If respiratory acidosis is the major disorder, then the serum HCO3 should be appropriately increased. If the serum HCO3 is not as high as expected, then metabolic acidosis also exists and the arterial pH may be substantially reduced. In contrast, if the serum HCO3 is higher than expected, then metabolic alkalosis complicates the respiratory acidosis and the arterial pH may be inappropriately \"normal.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with a high anion gap metabolic acidosis, a diagnosis of a mixed metabolic acidosis and a metabolic alkalosis generally requires calculation and interpretation of the",
"    <span class=\"nowrap\">",
"     &Delta;anion",
"    </span>",
"    gap and the",
"    <span class=\"nowrap\">",
"     &Delta;HCO3.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12584179\">",
"    <span class=\"h3\">",
"     Case 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the correct diagnosis may be more difficult with respiratory acid-base disorders, because of the difference between the acute and chronic compensatory responses. Consider the following arterial blood values: arterial pH 7.27, arterial PCO2 70 mmHg, and serum HCO3 31",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The low pH and hypercapnia indicate that the patient has respiratory acidosis. If this is acute hypercapnia, then the 30 mmHg rise in PCO2 should increase the serum HCO3 concentration by 3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (to about 27",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    If this is chronic hypercapnia, the serum HCO3 should increase by 11",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (to about 35",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    The observed value of 31",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    is between these expected levels and could have multiple explanations, including: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic respiratory acidosis with a superimposed metabolic acidosis that has reduced the serum HCO3 from 35 to 31",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      This might occur in a patient with chronic obstructive pulmonary disease who developed diarrhea due to viral gastroenteritis or lactic acidosis from sepsis.",
"     </li>",
"     <li>",
"      Acute respiratory acidosis with a superimposed metabolic alkalosis that has increased the HCO3 from 27 to 31",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      This could occur in a patient with respiratory depression due to a sedating drug who also developed vomiting or was taking diuretics.",
"     </li>",
"     <li>",
"      Acute respiratory acidosis superimposed on mild chronic respiratory acidosis. Suppose, for example, that a patient has chronic respiratory acidosis with a PCO2 of 55 mmHg and an appropriate serum HCO3 of 30",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      The patient then develops pneumonia, which acutely increases the pCO2 to 70 mmHg. The serum HCO3 would rise further to about 31",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      &nbsp;",
"     </li>",
"     <li>",
"      Acute respiratory acidosis that is evolving into a chronic disorder (between 1 and 3 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the correct diagnosis in a primary respiratory acid-base disorder can be established only when correlated with the clinical history and physical examination. This is true even when the arterial blood values appear to represent a simple disorder. If the serum HCO3 concentration had been 35",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in this example, the findings would have been compatible with an uncomplicated chronic respiratory acidosis. However, similar findings could have been induced by acute respiratory acidosis plus metabolic alkalosis. The history usually helps to distinguish among the possibilities and serial blood gas measurements and serum chemistries should be performed. (See",
"    <a class=\"local\" href=\"#H12584082\">",
"     'Respiratory acid-base disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365263262\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acid-base status is usually assessed by measuring the components of the bicarbonate-carbon dioxide buffer system in blood. When blood gas analysis is carried out, the partial pressure of CO2 (PCO2) and the pH are each measured using specific electrodes, and the serum bicarbonate (HCO3) concentration is calculated with the Henderson-Hasselbalch equation. When the HCO3 is measured in venous blood, it is usually measured directly as \"total CO2\" with an ion-selective electrode. The directly measured venous HCO3- is generally about 2",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      greater than the simultaneously calculated arterial HCO3. (See",
"      <a class=\"local\" href=\"#H12584019\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The range of normal values for acid-base parameters is different for arterial and venous samples and also varies among laboratories (see",
"      <a class=\"local\" href=\"#H102629685\">",
"       'Normal values according to site of sampling'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For an arterial sample, the normal range for pH is 7.36 to 7.44; for bicarbonate (HCO3) concentration, 21 to 27",
"      <span class=\"nowrap\">",
"       meq/L;",
"      </span>",
"      and for PCO2, 36 to 44 mmHg.",
"     </li>",
"     <li>",
"      For a peripheral venous sample, the range for pH is approximately 0.02 to 0.04 pH units lower than in arterial blood; for HCO3 concentration, approximately 1 to 2",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      higher; and for PCO2, approximately 3 to 8 mmHg higher.",
"     </li>",
"     <li>",
"      For a central venous sample, the range for pH is usually 0.03 to 0.05 pH units lower than in arterial blood, and the PCO2 is 4 to 5 mmHg higher, with little or no increase in serum HCO3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each simple acid-base disorder is normally associated with a compensatory respiratory or renal response that reduces the change in the",
"      <span class=\"nowrap\">",
"       HCO3/PCO2",
"      </span>",
"      ratio and therefore in pH (",
"      <a class=\"graphic graphic_figure graphicRef79833 \" href=\"UTD.htm?41/44/42691\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H351038132\">",
"       'Metabolic acid-base disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12584082\">",
"       'Respiratory acid-base disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a single disturbance of acid-base status, with the appropriate respiratory or renal compensation for that disturbance, is called a simple acid-base disorder. (See",
"      <a class=\"local\" href=\"#H12584039\">",
"       'Definitions of acid-base disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The simultaneous presence of more than one acid-base disturbance is called a mixed acid base disorder. Mixed acid-base disorders can be suspected from the patient's history, from a lesser- or greater-than-expected compensatory response, and from analysis of the",
"      <span class=\"nowrap\">",
"       &Delta;anion",
"      </span>",
"      gap and",
"      <span class=\"nowrap\">",
"       &Delta;HCO3.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12584039\">",
"       'Definitions of acid-base disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following three-step approach for the evaluation of most patients with acid-base disorders (See",
"      <a class=\"local\" href=\"#H360547043\">",
"       'Initial evaluation'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Establish the primary diagnosis. Metabolic acidosis is characterized by a low serum HCO3 and a low arterial pH; the serum anion gap may be increased or normal. Metabolic alkalosis is characterized by an elevated serum HCO3 and an elevated arterial pH. Respiratory acidosis is characterized by an elevated arterial PCO2 and a low arterial pH. Respiratory alkalosis is characterized by low arterial PCO2 and an elevated arterial pH. (See",
"      <a class=\"local\" href=\"#H360547043\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assess the degree of compensation as defined above for the individual disorders. If compensation is inadequate or excessive, this is indicative of a mixed acid-base disorder. (See",
"      <a class=\"local\" href=\"#H360547043\">",
"       'Initial evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12584047\">",
"       'Compensatory respiratory and renal responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determine if the anion gap is elevated. If it is, then analyze the ratio of the increase in anion gap to the decrease in the HCO3 concentration. This is the",
"      <span class=\"nowrap\">",
"       &Delta;anion",
"      </span>",
"      <span class=\"nowrap\">",
"       gap/&Delta;HCO3",
"      </span>",
"      ratio. When an anion gap acidosis exists, these changes should be quantitatively similar to one another; that is, the",
"      <span class=\"nowrap\">",
"       &Delta;anion",
"      </span>",
"      gap should be of similar magnitude as the",
"      <span class=\"nowrap\">",
"       &Delta;HCO3.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H360547043\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.328.",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/3\">",
"      Cengiz M, Ulker P, Meiselman HJ, Baskurt OK. Influence of tourniquet application on venous blood sampling for serum chemistry, hematological parameters, leukocyte activation and erythrocyte mechanical properties. Clin Chem Lab Med 2009; 47:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/4\">",
"      Kelly AM, Kyle E, McAlpine R. Venous pCO(2) and pH can be used to screen for significant hypercarbia in emergency patients with acute respiratory disease. J Emerg Med 2002; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/5\">",
"      Malatesha G, Singh NK, Bharija A, et al. Comparison of arterial and venous pH, bicarbonate, PCO2 and PO2 in initial emergency department assessment. Emerg Med J 2007; 24:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/6\">",
"      Chu YC, Chen CZ, Lee CH, et al. Prediction of arterial blood gas values from venous blood gas values in patients with acute respiratory failure receiving mechanical ventilation. J Formos Med Assoc 2003; 102:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/7\">",
"      Malinoski DJ, Todd SR, Slone S, et al. Correlation of central venous and arterial blood gas measurements in mechanically ventilated trauma patients. Arch Surg 2005; 140:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/8\">",
"      Walkey AJ, Farber HW, O'Donnell C, et al. The accuracy of the central venous blood gas for acid-base monitoring. J Intensive Care Med 2010; 25:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/9\">",
"      Adrogu&eacute; HJ, Madias NE. Secondary responses to altered acid-base status: the rules of engagement. J Am Soc Nephrol 2010; 21:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/10\">",
"      Wiederseiner JM, Muser J, Lutz T, et al. Acute metabolic acidosis: characterization and diagnosis of the disorder and the plasma potassium response. J Am Soc Nephrol 2004; 15:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/11\">",
"      Pierce NF, Fedson DS, Brigham KL, et al. The ventilatory response to acute base deficit in humans. Time course during development and correction of metabolic acidosis. Ann Intern Med 1970; 72:633.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.542.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/13\">",
"      Bushinsky DA, Coe FL, Katzenberg C, et al. Arterial PCO2 in chronic metabolic acidosis. Kidney Int 1982; 22:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/14\">",
"      Daniel SR, Morita SY, Yu M, Dzierba A. Uncompensated metabolic acidosis: an underrecognized risk factor for subsequent intubation requirement. J Trauma 2004; 57:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/15\">",
"      Albert MS, Dell RB, Winters RW. Quantitative displacement of acid-base equilibrium in metabolic acidosis. Ann Intern Med 1967; 66:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/16\">",
"      Fulop M. A guide for predicting arterial CO2 tension in metabolic acidosis. Am J Nephrol 1997; 17:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/17\">",
"      Javaheri S, Shore NS, Rose B, Kazemi H. Compensatory hypoventilation in metabolic alkalosis. Chest 1982; 81:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/18\">",
"      Javaheri S, Kazemi H. Metabolic alkalosis and hypoventilation in humans. Am Rev Respir Dis 1987; 136:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/19\">",
"      Madias NE, Schwartz WB, Cohen JJ. The maladaptive renal response to secondary hypocapnia during chronic HCl acidosis in the dog. J Clin Invest 1977; 60:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/20\">",
"      Madias NE, Adrogu&eacute; HJ, Cohen JJ. Maladaptive renal response to secondary hypercapnia in chronic metabolic alkalosis. Am J Physiol 1980; 238:F283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/21\">",
"      POLAK A, HAYNIE GD, HAYS RM, SCHWARTZ WB. Effects of chronic hypercapnia on electrolyte and acid-base equilibrium. I. Adaptation. J Clin Invest 1961; 40:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/22\">",
"      Brasseur L, De Coninck JD. The \"carbon dioxide response curve\" for chronic hypercapnia in man. N Engl J Med 1966; 275:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/23\">",
"      VAN YPERSELE DE STRIHOU C, GULYASSY PF, SCHWARTZ WB. Effects of chronic hypercapnia on electrolyte and acid-base equilibrium. III. Characteristics of the adaptive and recovery process as evaluated by provision of alkali. J Clin Invest 1962; 41:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/24\">",
"      Arbus GS, Herbert LA, Levesque PR, et al. Characterization and clinical application of the \"significance band\" for acute respiratory alkalosis. N Engl J Med 1969; 280:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/25\">",
"      Brackett NC Jr, Wingo CF, Muren O, Solano JT. Acid-base response to chronic hypercapnia in man. N Engl J Med 1969; 280:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/26\">",
"      Martinu T, Menzies D, Dial S. Re-evaluation of acid-base prediction rules in patients with chronic respiratory acidosis. Can Respir J 2003; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27288/abstract/27\">",
"      Krapf R, Beeler I, Hertner D, Hulter HN. Chronic respiratory alkalosis. The effect of sustained hyperventilation on renal regulation of acid-base equilibrium. N Engl J Med 1991; 324:1394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2352 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27288=[""].join("\n");
var outline_f26_41_27288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H365263262\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12584019\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102629685\">",
"      NORMAL VALUES ACCORDING TO SITE OF SAMPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360547531\">",
"      Arterial sample",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360547538\">",
"      Peripheral venous sample",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37165540\">",
"      Central venous sample",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12584039\">",
"      DEFINITIONS OF ACID-BASE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12584047\">",
"      COMPENSATORY RESPIRATORY AND RENAL RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141686354\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351038132\">",
"      Metabolic acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12584056\">",
"      - Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12584074\">",
"      - Metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H351038251\">",
"      - Limitations of the respiratory compensation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12584082\">",
"      Respiratory acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12584090\">",
"      - Respiratory acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12584098\">",
"      - Respiratory alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12584115\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360547043\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H377752461\">",
"      - Case 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H351037906\">",
"      - Case 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94198601\">",
"      Mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12584179\">",
"      - Case 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365263262\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2352\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2352|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/44/42691\" title=\"figure 1\">",
"      Expected compensation ranges for simple acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/38/31341\" title=\"figure 2\">",
"      Chronic respiratory acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/22/14702\" title=\"figure 3\">",
"      Acute respiratory disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/14/20717\" title=\"figure 4\">",
"      Chronic respiratory alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23224?source=related_link\">",
"      Chapter 10B: Buffers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=related_link\">",
"      Venous blood gases and other alternatives to arterial blood gases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_41_27289="Maintaining tsetse trap";
var content_f26_41_27289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Maintaining a tsetse trap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Local team during maintenance work of tsetse traps (type Lancien) in Northern Angola.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of August Stich, MD, MSc, DTMH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27289=[""].join("\n");
var outline_f26_41_27289=null;
var title_f26_41_27290="Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia";
var content_f26_41_27290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27290/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27290/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27290/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/41/27290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/41/27290/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/41/27290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome t(9;22)(q34;q11) resulting in the BCR-ABL fusion gene. This genetic abnormality results in the formation of a unique gene product (Bcr-Abl), a constitutively active tyrosine kinase that produces a continued proliferative signal resulting in the clinical manifestations of CML.",
"   </p>",
"   <p>",
"    Once this mechanism was understood, efforts were aimed at developing compounds that could selectively inhibit the aberrant tyrosine kinase resulting from this molecular rearrangement.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    mesylate (previously CFP-57148 or STI-571) was the first of these to be used in the treatment of CML. Since then, several other tyrosine kinase inhibitors (TKIs) have been developed and tested in patients with CML, most notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    (BMS-354825, Sprycel) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    (AMN 107,Tasigna). TKIs have become the initial treatment of choice for most patients with CML.",
"   </p>",
"   <p>",
"    This topic will review the clinical use of TKIs for the treatment of CML. The mechanisms of action and resistance will be discussed along with practical information about dosing, drug interactions, and management of side effects. The treatment options for chronic myeloid leukemia at various phases of disease and monitoring of disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    also inhibits c-kit and platelet-derived growth factor receptor (PDGFR), and has been successfully employed in other malignancies in which these kinases are mutated. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=see_link&amp;anchor=H21#H21\">",
"     \"Dermatofibrosarcoma protuberans\", section on 'Treatment of locally advanced, recurrent, and metastatic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=see_link\">",
"     \"Treatment of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tyrosine kinase inhibitors (TKIs) block the initiation of the Bcr-Abl pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. As described below, many of the TKIs also affect other signaling pathways. These differences in targeted pathways may be responsible for their varied clinical effects in tumors with different mechanisms of resistance to imatinib.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    competitively inhibits the inactive configuration of the Bcr-Abl protein tyrosine kinase by blocking the ATP binding site and thereby preventing a conformational switch to the active form (",
"    <a class=\"graphic graphic_figure graphicRef62594 \" href=\"UTD.htm?26/60/27585\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. It inhibits cellular proliferation and tumor formation without inducing apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/10\">",
"     10",
"    </a>",
"    ], and produces a 92 to 98 percent decrease in CML colony growth in vitro without inhibiting normal colony growth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/11\">",
"     11",
"    </a>",
"    ]. Imatinib also inhibits platelet-derived growth factor and c-kit, but not the Src family kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second generation TKIs inhibit both Bcr-Abl and other signaling pathways.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    inhibit both Bcr-Abl and Src kinases.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    is an inhibitor of Bcr-Abl, c-kit, and platelet derived growth factor receptor (PDGFR). Both nilotinib and dasatinib are &gt;100-fold more potent than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in vitro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to treatment with tyrosine kinase inhibitors (TKIs) is divided into two categories: primary and secondary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/13\">",
"     13",
"    </a>",
"    ]. Primary resistance is when a patient fails to achieve a desired response to treatment and occurs in up to 25 percent of patients receiving imatinib as initial treatment for chronic phase CML (",
"    <a class=\"graphic graphic_table graphicRef52082 \" href=\"UTD.htm?3/56/3981\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81376 \" href=\"UTD.htm?3/44/3789\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H19442906#H19442906\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Defining failure, suboptimal response, and optimal response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary resistance occurs when patients with an initial response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ultimately relapse. This proportion has been estimated at 80, 50, and 15 percent at approximately two years for patients in blast crisis, accelerated phase, or chronic phase, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary and secondary resistance may develop via different mechanisms and therefore will be discussed individually. There are no tests clinically available to accurately predict those patients who will have resistant disease or will develop resistance in the future. Ongoing studies are investigating the use of mutational screens, gene expression profiling, and in vitro Bcr-Abl activity assays to predict drug response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who appear to have resistant disease should be questioned carefully to assure that they are actually taking the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    at the recommended dose and schedule and whether they are taking other medications or herbal supplements which may impair efficacy of their TKI. Imatinib blood levels can and should be measured if there are questions about an individual's compliance with the medications. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Dosing and drug interactions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited information about mechanisms of primary resistance. There are two main mechanisms that are theoretically possible [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insufficient inhibition of the Bcr-Abl tyrosine kinase",
"     </li>",
"     <li>",
"      Decreased numbers of normal hematopoietic cells resulting in failure to recover normal blood counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inadequate blood levels of the TKI can be insufficient to inhibit the Bcr-Abl tyrosine kinase and low trough plasma levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    can be seen in some patients with primary resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, some patients with primary resistance can respond to increased doses of imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/15,21\">",
"     15,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Predicting primary resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence from a retrospective analysis suggests that gene expression signatures (classifier) from CD34+ cells can predict for major cytogenetic response or nonresponse to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in patients with chronic phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/22\">",
"     22",
"    </a>",
"    ]. There was an overlap between these classifier genes with CML progression signatures, suggesting that apparently chronic phase CML patients destined to fail treatment with imatinib have more advanced disease than is evident from morphologic or clinical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study will be required before gene expression profiling can be utilized to determine the selection of initial treatment for patients in chronic phase CML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Secondary resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of secondary resistance are varied but most commonly involve reactivation of Bcr-Abl signaling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the activation of other signaling pathways, such as Src kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Reactivation of Bcr-Abl",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is generally a consequence of reactivation of Bcr-Abl signaling, which can be due to BCR-ABL over expression, excretion of imatinib from the cell by transmembrane transporters, or, most commonly, by the development of single nucleotide mutations in Bcr-Abl which result in amino acid substitutions that change the conformation of the ATP binding site (P-loop), imatinib binding site, activation loop (controlling kinase activation), or catalytic domain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/12,24-27\">",
"     12,24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 50 such mutations have been described to date and have been associated with both primary and secondary resistance. In one study, amino acid substitutions at seven residues accounted for 85 percent of all resistance-associated mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/28\">",
"     28",
"    </a>",
"    ]. P-loop and T315I mutations were particularly frequent in advanced phase CML and Ph+ ALL patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/29\">",
"     29",
"    </a>",
"    ]. Mutations leading to clinical resistance appear to confer novel biological properties to the Bcr-Abl kinase that may affect disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/30\">",
"     30",
"    </a>",
"    ]; their appearance often accompanies progression from chronic phase to accelerated phase or blast crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some of these mutations confer only modest increases in the resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , others produce profound resistance in vitro and in vivo, which cannot be overcome by dose increases, or by the use of two newer TKIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genesis of these mutations is unclear; suggestions concerning their origin have included the presence of mutations in a small proportion of leukemic cells before treatment, development as a result of selective pressure from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , as well as self-mutagenesis of the Bcr-Abl kinase gene via reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/26,32-35\">",
"     26,32-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     T315I mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    are effective against most of the known BCR-ABL mutations, some of the mutations, most notably a mutation known as T315I, are resistant to high concentrations of both of these newer agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Ongoing clinical trials are evaluating the mutational status of patients treated with nilotinib and dasatinib and it may be possible in the future to tailor the choice of second line therapy according to the specific mutation in a given patient. Newer TKIs are currently being evaluated in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other signaling pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, resistance may be a consequence of activation of other, non",
"    <span class=\"nowrap\">",
"     Bcr/Abl-mediated",
"    </span>",
"    signaling pathways, such as the Src kinases. While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    does not directly inhibit members of the Src kinase family [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/11\">",
"     11",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    inhibit both Bcr-Abl and Src kinases.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    is an inhibitor of Bcr-Abl, c-kit, and platelet derived growth factor receptor (PDGFR). These non Bcr-Abl mediated mechanisms of resistance are not well understood at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DOSING AND DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    are metabolized by the CYP3A4 system and can inhibit other cytochrome P450 pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/44\">",
"     44",
"    </a>",
"    ]. As such, they have many drug interactions, notably including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . The international normalized ratio should be closely monitored in patients taking both warfarin and tyrosine kinase inhibitors (TKIs).",
"   </p>",
"   <p>",
"    Other medications and supplements that can affect the metabolism of these TKIs, lowering drug levels and thereby compromising its clinical efficacy, include St. John's wort (hypericum perforatum),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CYP3A4 inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and grapefruit juice can increase tyrosine kinase levels, and should be avoided if at all possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of St. John's wort\", section on 'Herb-drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended initial starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for patients in chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/47\">",
"     47",
"    </a>",
"    ] and 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for patients in accelerated phase or blast crisis, taken with food. Doses less than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are considered subtherapeutic and should rarely be used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/48\">",
"     48",
"    </a>",
"    ]. Imatinib can be given to most patients with liver or kidney dysfunction. Patients with moderate or severe liver dysfunction can either be dosed at 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with careful monitoring of liver function and toxicity or initially given 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with rapid escalation of the dose to 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as long as it is well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/49\">",
"     49",
"    </a>",
"    ]. No dose modifications are needed in the setting of mild to moderate renal dysfunction (up to creatinine clearance of 39",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    but imatinib should be used with caution in patients with severe renal dysfunction due to a lack of experience in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prescribing and toxicity information for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    are available; the approved dose is 70 mg PO twice per day for patients with more advanced CML or 100 mg PO once per day for patients in chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The lower dose of dasatinib (100 mg once per day) appears to have similar efficacy and a lower incidence of this and other side effects when studied in patients with chronic phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approved starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    is 400 mg PO twice daily in the setting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    failure and 300 mg PO twice daily for previously untreated disease. Nilotinib should be taken without food; dose adjustments may be needed for toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Nilotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most information about the side effects of tyrosine kinase inhibitors (TKIs) comes from long term studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . There are no long term data on the newer TKIs so there could be yet unknown long term side effects, although follow-up after three to four years of treatment with these drugs is reassuring in this regard. TKIs are generally very well tolerated; most side effects are mild (less than grade 2) and most patients can continue treatment without interruption. Alternatively, most symptoms resolve rapidly within a few days (rarely longer) after stopping the TKI for a brief \"drug holiday\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/56\">",
"     56",
"    </a>",
"    ]. Often, the drug can then be restarted at the same dose without a recurrence of the side effects.",
"   </p>",
"   <p>",
"    While often necessary to control side effects, extended &ldquo;drug holidays&rdquo; may affect disease response to therapy. In particular, a study employing an electronic device to monitor adherence with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy in 87 patients with CML in stable complete cytogenetic response on imatinib reported that adherence was an independent predictor of major molecular response (MMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients with &ge;90 percent adherence had a significantly higher rate of MMR at six years (95 versus 28 percent). No patients who took &le;80 percent of their prescribed dose attained a MMR.",
"   </p>",
"   <p>",
"    While the TKIs have some side effect profiles in common, there are some notable variations, which are enumerated below. Common side effects include myelosuppression, gastrointestinal complaints, fatigue, headache, rash, and peripheral and periorbital edema (most notably with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/36,58-62\">",
"     36,58-62",
"    </a>",
"    ]. Imatinib has been uncommonly associated with severe heart failure,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    are associated with QT prolongation, nilotinib can occasionally cause pancreatitis and dasatinib may cause pleural effusions as well as gastrointestinal bleeding probably related to an effect on platelet function.",
"   </p>",
"   <p>",
"    Many of these same side effects are also seen in patients with gastrointestinal (GI) stromal tumors treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . A discussion of side effects of imatinib in this scenario and their management can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H2#H2\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Efficacy of imatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The more common non-hematologic side effects of tyrosine kinase inhibitors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nausea and vomiting are generally not a problem when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      is taken with meals.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       Nilotinib",
"      </a>",
"      should be approximately two hours before or after meals.",
"     </li>",
"     <li>",
"      Diarrhea is usually mild (grade 1-2), but is occasionally more severe. It generally responds to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Muscle cramps, reported in 16 to 62 percent of patients, are perhaps the most bothersome long-term symptom associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . They typically affect the calves, feet, and hands. There is no definitive treatment, although anecdotally some patients have obtained benefit from calcium or magnesium supplements. Muscle cramps are uncommon with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Rash, seen in up to one-half of patients, is usually maculopapular and mild and usually resolves with continued treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/63-66\">",
"       63-66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link&amp;anchor=H3#H3\">",
"       \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Acneiform eruption'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic, low-grade toxicities from tyrosine kinase inhibitors affect the quality of life of some patients with CML, and attempts should be made to reduce or eliminate them whenever possible. A survey-based study evaluated health-related quality of life (HRQOL) in 448 patients with CML treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for a median of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/67\">",
"     67",
"    </a>",
"    ]. Older patients (&gt;60 years) had HRQOL scores similar to age-matched persons in the general population, while younger patients reported significantly worse HRQOL. Common toxicities included fatigue (82 percent), muscle cramps (78 percent), musculoskeletal pain (72 percent), and edema (69 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cytopenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although mild changes in hematologic parameters are common in chronic phase patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , it is unusual to have to interrupt therapy or modify dose due to myelosuppression. Blood counts should be obtained every one to two weeks during the first month of therapy, every two weeks during the second month, and periodically thereafter.",
"   </p>",
"   <p>",
"    As an example, in the largest phase III trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    as front line therapy for chronic phase CML, anemia, neutropenia, and thrombocytopenia occurred in 45, 60, and 57 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/68\">",
"     68",
"    </a>",
"    ]. However, grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    anemia, neutropenia, and thrombocytopenia occurred in 3, 14, and 8 percent of patients, respectively. These rates are increased when higher doses of imatinib are used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenia and thrombocytopenia are more likely due to suppression of the malignant clone, with variable delays in the recovery of normal hematopoiesis which had been suppressed by the CML clone, than to actual inhibition of normal hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with erythropoietin can be of benefit in the occasional patient with more severe anemia, but may be associated with thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/70\">",
"     70",
"    </a>",
"    ]. The safety of erythropoietic-stimulating agents (ESAs) was evaluated in a single center non-randomized cohort study of 608 patients with chronic phase CML treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , 217 of whom received ESAs at some point during their disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients given ESAs were older, more likely to be women, had a lower hemoglobin, and had a higher Sokal score. The median hemoglobin level achieved with ESAs was 12.9",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    ESA therapy was associated with hemoglobin increases of &gt;3",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    2 to 3",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    1 to &lt;2",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and &lt;1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in 55, 25, 15, and 5 percent, respectively. ESAs were associated with a higher rate of thrombosis (8.5 versus 2.6 percent), but did not appear to affect response rate or survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macrocytosis, with elevation of the mean corpuscular volume (MCV), is observed frequently; the mechanism is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link&amp;anchor=H9#H9\">",
"     \"Macrocytosis\", section on 'Imatinib and sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the occasional patient in chronic phase who experiences more significant myelosuppression, the drug should be stopped to allow recovery if the absolute neutrophil count (ANC) falls to",
"    <span class=\"nowrap\">",
"     &lt;1000/microL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the platelet count to",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL",
"    </span>",
"    during the first months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the ANC recovers to",
"      <span class=\"nowrap\">",
"       &gt;1500/microL",
"      </span>",
"      and the platelet count to &gt;75 to",
"      <span class=\"nowrap\">",
"       100,000/microL",
"      </span>",
"      within four weeks or less after stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , the drug should be restarted at full dose.",
"     </li>",
"     <li>",
"      If the ANC and platelet count recover slowly (ie, in &gt;4 weeks),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      should be restarted at a lower dose of 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and escalated to 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if myelosuppression has not recurred after four weeks at the lower dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once recovery of the blood count occurs, and particularly if a cytogenetic response is achieved, recurrence of myelosuppression is uncommon and most patients can be maintained at the 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    dose without further need for",
"    <span class=\"nowrap\">",
"     dose/schedule",
"    </span>",
"    modifications.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     Granulocyte colony-stimulating factor",
"    </a>",
"    may be helpful in treating neutropenia and allow improved delivery and effectiveness of tyrosine kinase inhibitors in occasional patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding, mainly affecting the gastrointestinal tract, occurs in up to 25 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    therapy and less frequently with other TKIs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/74-77\">",
"     74-77",
"    </a>",
"    ]. Such patients often have normal platelet counts and normal coagulation studies, but may have impaired platelet aggregation on stimulation with arachidonic acid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/78\">",
"     78",
"    </a>",
"    ]. The bleeding is typically mild to moderate and usually responds to a drug holiday.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;While uncommon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    has been associated with cardiac toxicities including edema and heart failure, which are sometimes severe. Animal and laboratory studies provide some insight into this association. Imatinib reduces left ventricular contractility in mice and is associated with histologic changes suggestive of a toxic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    related cardiac toxicity is low with grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    edema (1.3 percent),",
"    <span class=\"nowrap\">",
"     ischemia/infarction",
"    </span>",
"    (0.08 percent), hypertension (1 percent), and hypotension (0.7 percent) being the most worrisome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/58\">",
"     58",
"    </a>",
"    ]. Peripheral edema is more common in older patients and those with cardiac disease. Otherwise, periorbital edema is more common and, in contrast to peripheral edema, is more prominent in the morning and decreases as the patient is upright.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, severe heart failure (HF) has been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/79\">",
"     79",
"    </a>",
"    ]. It may be difficult to determine whether this problem is drug related or might have otherwise occurred in a middle aged to older patient population with a previous history of cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Larger studies have suggested that the incidence of HF in patients receiving imatinib for either hematologic disorders (eg, CML) or gastrointestinal stromal tumors is similar to what is expected in age-matched controls and is seen mainly in elderly patients with pre-existing cardiac conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further follow-up on this issue is desirable, but, in the interim, the following actions would be prudent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As part of the informed consent process, patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      should be notified that HF is a rare but serious adverse event.",
"     </li>",
"     <li>",
"      Patients currently taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      should be monitored by history and physical examination for signs and symptoms of left ventricular systolic dysfunction.",
"     </li>",
"     <li>",
"      HF should be considered in any patient experiencing edema while receiving this agent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link\">",
"       \"Clinical manifestations and diagnosis of edema in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     QT prolongation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    have been associated with QT prolongation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       Nilotinib",
"      </a>",
"      is associated with QT prolongation of &gt;30 ms or &gt;60 ms in approximately 33 and 2 percent of patients, respectively with a few reports of sudden death possibly associated with the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/84\">",
"       84",
"      </a>",
"      ]. The US Food and Drug Association issued a Risk Evaluation and Mitigation Strategy (REMS) to minimize the occurrence of QT prolongation and its sequelae in patients receiving nilotinib [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/85\">",
"       85",
"      </a>",
"      ]. Abnormalities in potassium and magnesium levels must be corrected prior to drug initiation, other drugs that may affect the QT interval should be avoided, and caution should be used in patients at risk for QT interval prolongation. Electrocardiograms should be obtained at baseline, after one week of treatment, with any dose change, and serially during therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       Dasatinib",
"      </a>",
"      may also prolong the QT interval and as such should be used carefully in patients at risk for QT prolongation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/60,86\">",
"       60,86",
"      </a>",
"      ]. Prolonged QT is seen in approximately 2 percent of patients on clinical trials of dasatinib [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/86\">",
"       86",
"      </a>",
"      ]. Low levels of magnesium or potassium should be corrected prior to initiating treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20491117\">",
"    <span class=\"h3\">",
"     Peripheral vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described the development of severe peripheral artery occlusive disease thought to be related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    in patients without other vascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. Nilotinib should be permanently discontinued in patients diagnosed with peripheral artery occlusive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328401472\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to 35 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      on phase I-II studies developed pleural effusions, most often exudative, some of which have required thoracentesis, insertion of a chest tube, pleurodesis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interruption or reduction of drug dosage. In a phase III dose optimization trial in patients in chronic phase, the occurrence of pleural effusion was decreased with dasatinib 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      dosing, without affecting short or long term efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/91\">",
"       91",
"      </a>",
"      ]. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H10#H10\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Dasatinib'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      This complication may also be more common in patients in accelerated or blast phase of CML treated with dasatinib. Other causes of effusion should be also be investigated in this patient population and treated appropriately [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/92\">",
"       92",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"       \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare cases of pulmonary arterial hypertension have been reported among patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/93,94\">",
"       93,94",
"      </a>",
"      ]. Dasatinib should be permanently discontinued in patients diagnosed with pulmonary arterial hypertension; resolution of the pulmonary hypertension has occurred after discontinuation in some patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H10#H10\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Dasatinib'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interstitial lung disease has also been reported in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H10#H10\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Dasatinib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      causes elevations in serum AST and ALT levels in 1 to 5 percent of patients, most commonly during the first 12 months. Hepatic toxicity can be severe. Fatal hepatotoxicity was noted in a patient in blast crisis who was taking large doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concurrently. As such, acetaminophen should be avoided in patients taking imatinib, if possible.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       Nilotinib",
"      </a>",
"      treatment can result in elevations in unconjugated bilirubin, lipase and amylase, all of which resolve with drug cessation and which are generally not accompanied by symptoms. Pancreatitis has been seen in approximately 1 percent of patients taking nilotinib [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/84\">",
"       84",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link&amp;anchor=H45#H45\">",
"       \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Molecularly targeted agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypophosphatemia has been reported, especially in patients taking larger doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/84,95,96\">",
"       84,95,96",
"      </a>",
"      ]. Routine monitoring of phosphate levels in patients taking imatinib has been suggested by the manufacturer [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/97\">",
"       97",
"      </a>",
"      ]. It is unknown whether hypophosphatemia might result in long term metabolic changes in bone, although one report noted increased trabecular bone volume in patients receiving long term imatinib [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/98\">",
"       98",
"      </a>",
"      ]. The mechanism is not known although it was postulated that imatinib may promote the maturation of osteoblasts and inhibit the maturation and function of osteoclasts via inhibition of platelet-derived growth factor.",
"     </li>",
"     <li>",
"      In one series, gynecomastia was noted in 7 of 38 men receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and was associated with reduced levels of free testosterone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tyrosine kinase inhibitors do not appear to be associated with an increased risk of second malignancy. An analysis of 1445 patients with CML or other hematologic malignancy treated with a TKI and followed for a median of 107 months reported rates of second cancers comparable to those in the Surveillance, Epidemiology, and End Results (SEER) database [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women of childbearing potential taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    have been advised not to become pregnant and that effective contraception, preferably barrier, should be used to prevent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/101\">",
"     101",
"    </a>",
"    ]. Women taking imatinib, dasatinib, or nilotinib are also advised to avoid breastfeeding.",
"   </p>",
"   <p>",
"    In preclinical studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    was found to be teratogenic in rats, but not rabbits, and impaired spermatogenesis was noted in rats, dogs, and monkeys [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/102\">",
"     102",
"    </a>",
"    ]. Information on the placental transport of imatinib in women is sparse. In one case report, imatinib, but not its active metabolite, was found in umbilical cord blood at the time of delivery, 12 hours after a maternal dose of imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/103\">",
"     103",
"    </a>",
"    ]. In a second case, neither imatinib nor its active metabolite was found in umbilical cord blood 38 hours after a maternal dose of imatinib. There is a paucity of data regarding the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    on fetal development. Animal studies of nilotinib did not find any effect on fertility but did report dose-dependent embryo and fetal toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/84\">",
"     84",
"    </a>",
"    ]. In one case report of a woman taking dasatinib for CML, pregnancy was identified at seven weeks gestation and was associated with fetal hydrops and severe fetal leukopenia and thrombocytopenia resulting in termination at 16 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/104\">",
"     104",
"    </a>",
"    ]. The fetal karyotype was normal. Dasatinib was detectable at near therapeutic levels in the fetal plasma.",
"   </p>",
"   <p>",
"    While conception among women or their male partners taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    may result in normal pregnancies, an effect on miscarriages and other birth abnormalities cannot be ruled out. Since damage to the fetus cannot be ruled out using information available at this time, and discontinuation of imatinib by the mother during pregnancy may result in disease relapse, it is strongly recommended that patients with CML should practice adequate means of contraception while on treatment, and that this agent should not be administered to patients during pregnancy or lactation.",
"   </p>",
"   <p>",
"    Advice for patients who have become pregnant despite the above recommendations is difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/101\">",
"     101",
"    </a>",
"    ]. Continuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    may result in damage to the developing fetus, while its discontinuation may result in disease relapse in the mother. In some cases, couples have decided on therapeutic termination of the pregnancy, others have continued treatment throughout the pregnancy, while others have discontinued imatinib and were treated with other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , interferon, leukapheresis) during the remainder of the pregnancy, with reinstitution of imatinib following delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/105\">",
"     105",
"    </a>",
"    ]. Interferon is an FDA pregnancy risk category C (risk cannot be ruled out) medication, but our clinical experience is that it appears to be safe during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=see_link\">",
"     \"Interferon alpha for the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of sufficient information concerning risks and benefits, personal preferences of the involved couple, along with input from a hematologist as well as an obstetrician expert in the detection of fetal abnormalities, will weigh heavily in the final decision [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/101,106\">",
"     101,106",
"    </a>",
"    ]. This will be of special importance in a woman who has achieved a complete molecular remission, since a return to that status cannot be guaranteed if a TKI is discontinued for any appreciable length of time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Aims of initial therapy and duration of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mothers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no prospective clinical trials that have collected data on the pregnancy outcomes of women exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Only case series of such women are available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/101,102,107-112\">",
"     101,102,107-112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest of these series included 180 women exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    during pregnancy of whom 125 (69 percent) had known pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/113\">",
"     113",
"    </a>",
"    ]. Of these patients with known outcomes, 63 (50 percent) delivered normal infants, 35 (28 percent) elected termination of the pregnancy, and 18 (14 percent) had a spontaneous abortion. Abnormalities were identified in 12 infants. The specific abnormalities varied but included exophthalmos, renal agenesis, hemivertebrae, and hypospadias. These data support concern over the use of imatinib during pregnancy and the continued recommendation that contraceptives be used by individuals with reproductive potential.",
"   </p>",
"   <p>",
"    In a case report in a lactating mother taking 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , concentrations of imatinib and its major metabolite in her milk were approximately 50 to 90 percent of that in her plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/114\">",
"     114",
"    </a>",
"    ]. In this and another case, it was estimated that an infant consuming 600 to 1000 mL of milk would ingest between 1.2 and 3.0 mg of these materials daily [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/103,114\">",
"     103,114",
"    </a>",
"    ]. Although the significance of these findings is unclear, it would seem prudent for a woman taking imatinib to avoid breastfeeding.",
"   </p>",
"   <p>",
"    Although not recommended, some patients may choose to temporarily discontinue therapy in order to conceive a child. For women, this would require a cessation of therapy for a prolonged period of time and raises a question regarding the ideal timing of such a long lapse in therapy. A case series of seven women with CML who temporarily discontinued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for the length of their pregnancy reported that all of these patients lost their cytogenetic response and four lost complete hematologic response during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/115\">",
"     115",
"    </a>",
"    ]. The three patients who had a major molecular response (MMR) at the time of discontinuation were able to regain this MMR upon retreatment. However, of the four patients who had only achieved a complete cytogenetic response or major cytogenetic response prior pregnancy, two were unable to regain the level of response they had previously attained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fathers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience in clinical trials and anecdotal reports have generally not shown evidence for reduced sperm counts or infertility in males taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/102\">",
"     102",
"    </a>",
"    ]. There is limited information concerning the outcomes of pregnancies among partners of men treated with imatinib.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2003 review, there were 13 pregnancies in partners of men taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , with one spontaneous and two therapeutic abortions, one death in utero at 13 weeks, and four normal infants delivered at the time of publication [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single institution report, there were nine pregnancies in eight partners of men taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , with one spontaneous abortion and the birth of eight healthy babies, one of whom was born with small intestinal rotation requiring surgery shortly after birth [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a short report, there were five pregnancies in four partners of men taking long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ; all pregnancies were uneventful [",
"      <a class=\"abstract\" href=\"UTD.htm?26/41/27290/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tyrosine kinase inhibitors (TKIs) block the action of the Bcr-Abl pathway.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      competitively inhibits the inactive configuration of the Bcr-Abl protein tyrosine kinase by blocking the ATP binding site and thereby preventing a conformational switch to the active form. Other TKIs can affect additional signaling pathways which may be responsible for their varied clinical effects in tumors with different mechanisms of resistance to imatinib. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are varied mechanisms of resistance in patients who have a suboptimal initial response (primary resistance) or relapse after an initial response (secondary resistance) to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      are metabolized by the CYP3A4 system and can inhibit other cytochrome P450 pathways. As such, there are numerous interactions with medications and herbal supplements. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dosing and drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TKIs are generally very well tolerated with only mild side effects. Most symptoms resolve rapidly within a few days after stopping the TKI for a brief \"drug holiday\" and the drug can often be restarted at the same dose without a recurrence of the side effects. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management of side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For male and female patients of childbearing age, we recommend the use of contraception while on treatment with TKIs (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the event of a pregnancy while on treatment with a TKI, the patient, obstetrician, and hematologist should have a detailed discussion about possible termination of the pregnancy, the risks of continued treatment with a TKI throughout the pregnancy, or use of other agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      , interferon, leukapheresis) during the remainder of the pregnancy, with reinstitution of the TKI following delivery. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/1\">",
"      Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/2\">",
"      Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005; 104:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/3\">",
"      Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/4\">",
"      Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/5\">",
"      Kantarjian HM, Giles F, Quint&aacute;s-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007; 13:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/6\">",
"      Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/7\">",
"      Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001; 6:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/8\">",
"      Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. N Engl J Med 2002; 346:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/9\">",
"      Tsao AS, Kantarijian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol 2002; 119:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/10\">",
"      Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/11\">",
"      Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/12\">",
"      Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/13\">",
"      Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program 2007; :371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/14\">",
"      O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004; 103:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/15\">",
"      Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/16\">",
"      Kantarjian H, Talpaz M, O'Brien S, et al. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 97:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/17\">",
"      Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/18\">",
"      Mizutani T, Kondo T, Darmanin S, et al. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells. Clin Cancer Res 2010; 16:3964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/19\">",
"      Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009; 27:3642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/20\">",
"      Milojkovic D, Apperley J. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin Cancer Res 2009; 15:7519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/21\">",
"      Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003; 102:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/22\">",
"      McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010; 115:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/23\">",
"      Oehler VG, Yeung KY, Choi YE, et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009; 114:3292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/24\">",
"      Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/25\">",
"      Kantarjian HM, Talpaz M, Giles F, et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/26\">",
"      O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/27\">",
"      White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/28\">",
"      Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12:7374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/29\">",
"      Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008; 113:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/30\">",
"      Skaggs BJ, Gorre ME, Ryvkin A, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A 2006; 103:19466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/31\">",
"      O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/32\">",
"      Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/33\">",
"      Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/34\">",
"      Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/35\">",
"      Nowak D, Ogawa S, M&uuml;schen M, et al. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 2010; 115:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/36\">",
"      Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 354:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/37\">",
"      von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/38\">",
"      Soverini S, Martinelli G, Colarossi S, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 2006; 24:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/39\">",
"      Lee TS, Potts SJ, Kantarjian H, et al. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 2008; 112:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/40\">",
"      Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/41\">",
"      Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111:4355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/42\">",
"      O'Hare T, Eide CA, Tyner JW, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A 2008; 105:5507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/43\">",
"      Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/44\">",
"      Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011; 117:e75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/45\">",
"      Smith PF, Bullock JM, Booker BM, et al. Induction of imatinib metabolism by hypericum perforatum. Blood 2004; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/46\">",
"      Smith P, Bullock JM, Booker BM, et al. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004; 24:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/47\">",
"      Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/48\">",
"      Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/49\">",
"      Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/50\">",
"      Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:570.",
"     </a>",
"    </li>",
"    <li>",
"     Available from the US FDA website at file://www.fda.gov/cder/foi/label/2006/021986lbl.pdf (Accessed on September 06, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/52\">",
"      Dasatinib (Sprycel) for CML and Ph + ALL. Med Lett Drugs Ther 2007; 49:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/53\">",
"      Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008; 14:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/54\">",
"      Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204.",
"     </a>",
"    </li>",
"    <li>",
"     Available from the US FDA website at www.fda.gov/cder/foi/label/2007/022068lbl.pdf (Accessed on October 31, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/56\">",
"      Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer 2011; 117:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/57\">",
"      Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/58\">",
"      Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/59\">",
"      Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/60\">",
"      Khoury HJ, Guilhot F, Hughes TP, et al. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009; 115:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/61\">",
"      Koren-Michowitz M, le Coutre P, Duyster J, et al. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer 2010; 116:4564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/62\">",
"      Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/63\">",
"      Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001; 345:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/64\">",
"      Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/65\">",
"      Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002; 100:3434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/66\">",
"      Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/67\">",
"      Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118:4554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/68\">",
"      O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/69\">",
"      Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/70\">",
"      Cortes J, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004; 100:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/71\">",
"      Santos FP, Alvarado Y, Kantarjian H, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 2011; 117:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/72\">",
"      Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004; 100:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/73\">",
"      Quint&aacute;s-Cardama A, De Souza Santos FP, Kantarjian H, et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009; 115:3935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/74\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009; 115:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/75\">",
"      Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/76\">",
"      Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/77\">",
"      Gratacap MP, Martin V, Val&eacute;ra MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/78\">",
"      Quint&aacute;s-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009; 114:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/79\">",
"      Kerkel&auml; R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/80\">",
"      Mann DL. Targeted cancer therapeutics: the heartbreak of success. Nat Med 2006; 12:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/81\">",
"      Hatfield A, Owen S, Pilot PR. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13:13; author reply 15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/82\">",
"      Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/83\">",
"      Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/84\">",
"      Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14:5325.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM217737.pdf (Accessed on August 20, 2010).",
"    </li>",
"    <li>",
"     Brave M, et al. Briefing document for Oncology Drug Advisory Committee. Available at: &lt;www.fda.gov/ohrms/dockets/AC/06/briefing/2006-4220-B1-02FDA-Background.pdf&gt;. Accessed on December 15, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/87\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/88\">",
"      Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/89\">",
"      Gambacorti-Passerini C, Piazza R. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in \"long-term\" safety and efficacy. Am J Hematol 2011; 86:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/90\">",
"      Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/91\">",
"      Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/92\">",
"      Goldblatt M, Huggins JT, Doelken P, et al. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci 2009; 338:414.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm275176.htm (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/94\">",
"      Montani D, Bergot E, G&uuml;nther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/95\">",
"      Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/96\">",
"      Osorio S, Noblejas AG, Dur&aacute;n A, Steegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007; 82:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/97\">",
"      Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:627; author reply 628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/98\">",
"      Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/99\">",
"      Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet 2003; 361:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/100\">",
"      Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011; 118:4353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/101\">",
"      Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw 2009; 7:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/102\">",
"      Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003; 40:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/103\">",
"      Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007; 27:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/104\">",
"      Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs 2012; 23:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/105\">",
"      Kobayashi K, Takebayashi C, Miyata S, et al. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia. Intern Med 2009; 48:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/106\">",
"      Ali R, Ozkalemkas F, Ozcelik T, et al. Imatinib and pregnancy. J Clin Oncol 2006; 24:3812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/107\">",
"      Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/108\">",
"      Heartin E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 2004; 45:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/109\">",
"      Prabhash K, Sastry PS, Biswas G, et al. Pregnancy outcome of two patients treated with imatinib. Ann Oncol 2005; 16:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/110\">",
"      AlKindi S, Dennison D, Pathare A. Imatinib in pregnancy. Eur J Haematol 2005; 74:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/111\">",
"      Ali R, Ozkalemka F, Oz&ccedil;elik T, et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005; 29:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/112\">",
"      Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 2006; 17:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/113\">",
"      Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111:5505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/114\">",
"      Gambacorti-Passerini CB, Tornaghi L, Marangon E, et al. Imatinib concentrations in human milk. Blood 2007; 109:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/115\">",
"      Kuwabara A, Babb A, Ibrahim A, et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 2010; 116:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/41/27290/abstract/116\">",
"      Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007; 137:374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4509 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27290=[""].join("\n");
var outline_f26_41_27290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Predicting primary resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Secondary resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Reactivation of Bcr-Abl",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - T315I mutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other signaling pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DOSING AND DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cytopenias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - QT prolongation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20491117\">",
"      - Peripheral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H328401472\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mothers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fathers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4509|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/60/27585\" title=\"figure 1\">",
"      Imatinib mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/56/3981\" title=\"table 1\">",
"      Response definitions CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/44/3789\" title=\"table 2\">",
"      CML treatment milestones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=related_link\">",
"      Clinical use of St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=related_link\">",
"      Interferon alpha for the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=related_link\">",
"      Treatment of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_41_27291="The modified Bishop score";
var content_f26_41_27291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Bishop scoring system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        0",
"       </td>",
"       <td class=\"subtitle1\">",
"        1",
"       </td>",
"       <td class=\"subtitle1\">",
"        2",
"       </td>",
"       <td class=\"subtitle1\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilation, cm",
"       </td>",
"       <td>",
"        Closed",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        5-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Effacement, percent",
"       </td>",
"       <td>",
"        0-30",
"       </td>",
"       <td>",
"        40-50",
"       </td>",
"       <td>",
"        60-70",
"       </td>",
"       <td>",
"        &ge;80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Station*",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        -1, 0",
"       </td>",
"       <td>",
"        +1, +2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical consistency",
"       </td>",
"       <td>",
"        Firm",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Soft",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Position of the cervix",
"       </td>",
"       <td>",
"        Posterior",
"       </td>",
"       <td>",
"        Midposition",
"       </td>",
"       <td>",
"        Anterior",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on a -3 to +3 scale.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27291=[""].join("\n");
var outline_f26_41_27291=null;
var title_f26_41_27292="Mgmt fecal incontinence ACG I";
var content_f26_41_27292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Gastroenterology recommendations for management of fecal incontinence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with fecal incontinence may be categorized into passive or urge incontinence or fecal seepage and their severity can be graded on a prospective stool diary and clinical features.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should include a detailed physical and neurological examination of the back and lower limbs to evaluate for a systemic or neurological disorder.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digital rectal examination can identify patients with fecal impaction and overflow but is not accurate enough for diagnosing sphincter dysfunction or initiating therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Investigations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopic evaluation of the rectosigmoid region is appropriate for detecting mucosal disease or neoplasia that may contribute to fecal incontinence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorectal manometry with rectal sensory testing is the preferred method for defining the functional weakness of the external or internal anal sphincter and for detecting abnormal rectal sensation. Measurement of rectal compliance (reservoir function) may be helpful in some patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Imaging of the anal canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anal endosonography is the simplest, most widely available and least expensive test for defining structural defects in the anal sphincter and should be considered in patients with suspected fecal incontinence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Defecography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is useful in patients with suspected rectal prolapse or those with poor rectal evacuation but is otherwise of limited value.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Balloon expulsion test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can identify impaired evacuation in patients with fecal seepage or in those with fecal impaction and overflow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pudendal nerve terminal latency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be useful in the assessment of patients prior to anal sphincter repair and is particularly helpful in predicting the outcome of surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Saline infusion test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can serve as a simple method for evaluating fecal incontinence, in particular for assessing clinical improvement after surgery or biofeedback therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rao, SS. Diagnosis and management of fecal incontinence. Am J Gastroenterol 2004; 99:1585.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27292=[""].join("\n");
var outline_f26_41_27292=null;
var title_f26_41_27293="AED for primary generalized tonic-clonic seizures";
var content_f26_41_27293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of primary generalized tonic-clonic seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily adult dosage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual dosing interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Primary generalized tonic-clonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Valproate",
"        <sup>",
"         &bull;,&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Lamotrigine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Levetiracetam",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Some alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Carbamazepine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        800-1800 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        10-30 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Topiramate",
"       </td>",
"       <td>",
"        25-50 mg",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        1-3 mg/kg",
"       </td>",
"       <td>",
"        5-9 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg**",
"       </td>",
"       <td>",
"        6-8 mg/kg**",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Oxcarbazepine",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        300-600 mg",
"       </td>",
"       <td>",
"        900-2400 mg",
"       </td>",
"       <td>",
"        8-10 mg/kg",
"       </td>",
"       <td>",
"        6-51 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Phenytoin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        300-400 mg",
"       </td>",
"       <td>",
"        300-400 mg",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        5 mg/kg",
"       </td>",
"       <td>",
"        4-8 mg/kg",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosage may need to be adjusted for renal or hepatic impairment, or concomitant use of other drugs.",
"     <br>",
"      &bull; Measurement of serum concentrations may be useful to guide therapy. Usual therapeutic serum concentrations are: carbamazepine 6-12 mcg/mL, phenobarbital 15-35 mcg/mL, phenytoin 10-20 mcg/mL, valproate 50-120 mcg/mL. Some patients achieve complete seizure control at lower concentrations, and occasional patients need higher concentrations.",
"      <br>",
"       &Delta; Not FDA-approved unless absence is involved.",
"       <br>",
"        &loz; Once daily for the extended-release formulation (Depakote ER).",
"        <br>",
"         &sect; FDA-approved for adjunctive therapy in adults and children &ge;2 years old with partial seizures, with Lennox-Gastaut syndrome or with primary generalized seizures, and as monotherapy in adults with partial seizures as a substitute for carbamazepine, phenytoin, phenobarbital or valproate.",
"         <br>",
"          &yen; Starting dosage is 25 mg every other day and maintenance dosage is 100 to 400 mg daily when given with valproate.",
"          <br>",
"           &Dagger; Starting dosage is 0.15 mg/kg daily and maintenance dosage is 1 to 5 mg/kg daily when given with valproate.",
"           <br>",
"            &dagger; Not FDA-approved for this indication.",
"            <br>",
"             ** Not FDA-approved for pediatric use.",
"             <br>",
"              &bull;&bull; Adjustments in maintenance dosage above 300 mg/day for adults should usually be made in 25- or 30-mg increments because metabolism becomes saturated.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70): 37-46. Copyright &copy;2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27293=[""].join("\n");
var outline_f26_41_27293=null;
var title_f26_41_27294="Mallet finger with DIPJ subluxation";
var content_f26_41_27294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mallet finger with DIPJ subluxation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 190px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mallet fractures result from sudden forced flexion of an extended distal interphalangeal joint (DIPJ), resulting in avulsion of the attachment of the extensor tendon. If subluxation of the DIPJ is present as shown here, the patient may need open reduction and should be referred to a hand surgeon within two to three days.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27294=[""].join("\n");
var outline_f26_41_27294=null;
var title_f26_41_27295="Trapezoid edema T1 MRI";
var content_f26_41_27295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trapezoid edema on T1 MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T1-weighted, axial magnetic resonance image of the wrist shows decreased signal intensity throughout the trapezoid, when compared to the strength of the signal from the trapezium (Tm), capitate (C), and hamate (H) bones. This suggests the presence of edema consistent with microtrabecular injury. The trapezoid is the dark-appearing bone between the trapezium and capitate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_41_27295=[""].join("\n");
var outline_f26_41_27295=null;
